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Tobramycin disposition following airway administration was evaluated by meta-analysis of 
human data in the literature and, experimentally, using a realistic ex vivo model, the isolated 
perfused rat lung preparation (IPRL). Pulmonary bioavailability of inhaled tobramycin in 
published studies was re-evaluated separately for CF and healthy adults, with the drug’s intrinsic 
pharmacokinetic (PK) parameters obtained from intravenous (IV) studies in the literature. While 
 
 
large variations in tobramycin’s clearance precluded accurate assessment of its bioavailability, the 
results were indicative of substantial pulmonary absorption, in spite of its hydrophilic and poly 
cationic properties. To explore its disposition kinetics and mechanisms following airway 
administration, tobramycin absorption was investigated as a function of dose in the IPRL. The 
cumulative fraction of the administered tobramycin dose reaching the perfusate versus time, was 
bi-exponential and dose-dependent, unlike that of the marker solutes fluorescein and mannitol, 
both of which showed first-order and dose-independent kinetics. A kinetic model that incorporated 
lung tissue binding (or sequestration) alongside passive absorption was employed successfully to 
describe the aminoglycoside’s disposition in the IPRL following airway administration. 
Tobramycin’s absorption was fast with the first-order absorption rate constants (0.065-0.070 min-
1) close to those seen with fluorescein (0.076 min-1), but a dose-, and concentration-dependent slow 
onset tissue binding prolonged its presence in the rat lung. Binding was confirmed by independent 
dynamic dialysis experiments using sliced lung prepared from the intact IPRL, immediately 
following airway administration using an identical technique as that used in tobramycin absorption 
studies. Dosing solution osmolality and pH had negligible effects on the drug’s disposition in the 
IPRL, when these were investigated over experimental ranges that could be used clinically. While 
tobramycin itself was found to accelerate mannitol’s absorption, and thus affect airway epithelial 
integrity when administered at high doses, the effect was undetectable at a dose level in rat lungs 
that was believed to produce airway concentrations corresponding to those in human patients using 
TOBI®. These findings may partly explain the apparent success of inhaled tobramycin therapy in 
the treatment of pulmonary infections.  
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Chapter I 
BACKGROUND AND SIGNIFICANCE 
 
 
 
Tobramycin administration direct to the airways via nebulizer has brought great improvements 
to the health and wellbeing of cystic fibrosis (CF) patients and others suffering from chronic 
pulmonary infections with pathogens such as Pseudomonas aeruginosa (Chuchalin et al., 2009). 
The topical administration of this class of antibiotics by inhalation offers an attractive alternative, 
delivering high concentrations of drug directly to the site of infection while minimizing the risk of 
toxicities associated with high systemic exposure (Geller et al., 2002; Touw et al., 1995). Although 
the efficacy and safety of inhaled tobramycin is well-recognized in clinical circles, its absorption 
and disposition following airway administration has not been thoroughly studied in humans and 
animals, and it remains possible that its pulmonary disposition influences its efficacy. 
 
Historically, tobramycin has been administered parenterally for treatment of lung infections 
with limited success; serum to lung drug concentration ratios of 10:1 are typical (Moriarty et al., 
2007), meaning that high serum concentrations are required to get sufficient drug into the airways 
and these often caused toxicity (Selimoglu, 2007; Todd and Hottendorf, 1995). These observations, 
taken with tobramycin’s extremely poor oral bioavailability (Jaresko and Alexander, 1995; Phillips 
and Shannon, 1997), all appear to be associated with the low permeability of epithelia to this 
hydrophilic drug. Tobramycin’s biopharmaceutical properties may be further complicated by the 
drug’s tendency to accumulate in or on certain epithelial cells, e.g. in the kidney or inner ear 
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(Mingeot-Leclercq and Tulkens, 1999; Selimoglu, 2007). Clearly, topical administration of 
tobramycin by nebulizer has the advantage that high concentrations may be targeted to the airways 
where its antimicrobial effect is believed to be concentration-dependent and its efficacy is related 
to the magnitude of the airway Cmax (the peak level of drug concentration in the airways) to MIC 
(minimum inhibitory concentration) ratio (MacArthur et al., 1984). However, the ideal duration 
over which concentration should be maintained in the airways of infected patients is unknown. 
 
In general, tobramycin bioavailability from the lung following inhalation is therefore presumed 
to be slow and incomplete, in favor of sustaining its local antimicrobial activities in the airways, 
due to its hydrophilicity and polycationic properties at physiologic pH (Pai and Nahata, 2001; Poli 
et al., 2007).  However, tobramycin studies in the lung following inhalation are quite limited, and 
there is insufficient published scientific evidence to support this theory. In the study of Cooney et 
al., mean absolute bioavailability (±SD) in 6 CF adults was estimated to be 9.1 (±3.8) %, based on 
the ratios of AUC (area under drug serum concentration versus time curve) normalized by dose 
(Cooney et al., 1994). In this case, the data was normalized based on the “emitted dose” from the 
nebulizer (Microstate Ultra Nebulizer was used for inhalation) compared to the intravenous (IV) 
dose as the reference; notably, however, the true lung dose was not determined. Tobramycin 
pulmonary bioavailability was also assessed using a population pharmacokinetic approach for 
multiple doses (twice daily for 28 days) of TOBI® (300 mg in 5 mL 0.25 normal saline; Chiron 
Corporation; Seattle, WA) administered via a jet nebulizer (PARI LC; Pari Respiratory; Richmond, 
VA) in a phase III clinical trial in which 258 CF patients were enrolled (Geller et al., 2002). In that 
study, the bioavailability of inhaled tobramycin was reported as 11.7 %, calculated using the 
“population estimate of the apparent clearance” (CL/F= 49.6 L/h) with an average value for 
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systemic clearance, CL of 5.79 L/h from 3 published IV studies (Geller et al., 2002). Geller’s result 
was comparable with that from Touw et al. (1997), given the large inter-patient variations in both 
studies; Touw et al. estimated bioavailability at 17.5% based on the urinary output of 6 CF adults 
after a single dose of 600 mg tobramycin via an ultrasonic nebulizer (WISTO SENIOR; Wisto, 
Woerden, Netherlands) (Touw et al., 1997).  
 
Notably, the fractions of the administered doses depositing in the lung immediately following 
tobramycin inhalation were determined in none of the studies described above. Therefore, values 
for pulmonary bioavailability were calculated based on the nominal doses loaded in the nebulizer 
or the emitted doses believed to be delivered from them. Due to the generally inefficient lung 
delivery of nebulizer devices, large drug losses are expected during drug administration and only 
a small dose fraction can reach the capillary-perfused regions for absorption into the systemic 
circulation (Coates et al., 2000; Touw et al., 1995). The fraction of each administered dose 
eventually deposited in the lung depends on the device, formulation and the airways geometry and 
breath patterns of users; the average percentage of loaded dose is expected to range between 5 and 
15% for the ultrasonic and jet nebulizers used in these studies (Ilowite et al., 1987; Lenney et al., 
2011; Touw et al., 1997). In this scenario therefore, although tobramycin pulmonary 
bioavailability was stated to be low (Cooney et al., 1994; Geller et al., 2002), the results indicate 
that the systemically available fractions of  the total lung doses (mass deposited in the lung region) 
delivered by nebulizer may actually approach 1, in spite of the drug’s ionization and hydrophilicity. 
 
In the study of Cooney et al., the absorption rate was also assessed after calculating the 
cumulative fraction of drug absorbed as function of time using the Loo-Riegelman method 
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(Cooney et al., 1994). The mean absorption time estimated for the 6 subjects ranged from 0.25 to 
1.5 hours. Due to the small number of subjects and large inter-subject variability seen in this study, 
the reliability of this result is debatable. In the study of Touw et al., the first-order absorption rate 
constant (ka) for tobramycin after inhalation was estimated using compartmental pharmacokinetic 
(PK) analysis; values were reported in the range of 0.56-4.16 hr-1 with wide inter-subject variations 
(Touw et al., 1997), while the terminal t1/2, which referred to the half life of the terminal phase of 
drug serum concentration time profiles, ranged from 8.9 to 19.3 hours (Touw et al., 1997). In this 
study, this prolonged terminal t1/2, compared to those observed typically in IV studies in the range 
of 1.5 to 3 hours (Levy et al., 1984; Touw et al., 1993; Town et al., 1996), was interpreted to be 
due to the phenomenon of “flip-flop” that implied a delayed absorption from a depot of tobramycin 
in the lung. Similarly, the prolonged terminal t1/2 (about 8 hours) following inhalation was also 
observed in another study conducted by Conte et al. in healthy volunteers (Conte et al., 1993). 
While these prolonged serum half-lives have been observed, the values are not consistent with 
those for absorption from Cooney et al.(1994); nor has the phenomenon been seen in other studies 
with similar designs (Geller et al., 2002; Newhouse et al., 2003; Pilcer et al., 2008; Poli et al., 
2007). The discrepancies may be attributed to differences in study designs, sampling duration and 
frequencies, PK analysis methods, accuracy, precision and LLOQ (lower limit of quantification) 
of assay methods, as well as variations between subjects, studies, and dosing regimens. Overall 
however, the reports emphasize our poor understanding of pulmonary absorption and disposition. 
 
Despite this controversy, tobramycin is believed to exit the lung slowly following inhalation. 
This theory may be derived from the persistence of high tobramycin concentration in airway 
secretions following inhalation in animals and humans (Eisenberg et al., 1997; Gibson et al., 2003; 
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Lenoir et al., 2007; Valcke and Pauwels, 1991). Evidence of high alveolar lining fluid (ALF) 
concentrations that persisted for as long as 6 hours and remained far in excess of the MIC 
(minimum inhibitory concentration) of susceptible respiratory pathogens was shown in rats 
following endotracheal administration (Valcke and Pauwels, 1991). In humans, potential 
tobramycin accumulation in respiratory secretions with repeated dosing TOBI (300 mg b.i.d.) in 
young CF patients (≤6 years old) was also observed (Gibson et al., 2003), although a short half life 
of drug disappearance from sputum was generally found after single dose administration (Geller 
et al., 2003; Weber et al., 1994). Tobramycin persistence in ALF of pneumonia patients collected 
by bronchoalveolar lavage (BAL) was also shown in a clinical trial after IV administration, in 
which a slower rate of drug disappearance occurred from ALF than from serum (Carcas et al., 
1999) was thought to indicate that the ALF constituted a deep compartment for tobramycin.  
Moreover, in vitro studies also found that tobramycin bound to sputum and that binding appeared 
saturable (Mendelman et al., 1985). In spite of these results, however, tobramycin binding or 
sequestration in the lung and the extent to which binding actually affects the drug’s disposition 
following inhalation has not been studied. 
 
While the sites and mechanisms of drug binding or sequestration in lung tissue remain to be 
investigated, the drug’s multiple positive charges and the presence of “ubiquitous negative charges 
on the surface of cell membranes” has been mentioned as one type of possible interaction in the 
airways (Patton et al., 2004). The hypothesis was inferred partly from results of the studies of 
aminoglycosides’ nephrotoxicity, in which the drugs were believed to initially bind to acidic 
phospholipids in the brush-border membrane of proximal tubule cells and then cause accumulation 
of this class of drugs in the epithelial cells of renal proximal tubules (Nagai and Takano, 2004). 
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Notably, aminoglycosides’ binding to proximal tubule and inner ear cells has been investigated for 
the studies of aminoglycoside nephrotoxicity and ototoxicity. Since there are the similarities in 
composition and structure (phospholipid bilayers) among epithelial membranes, the binding of 
aminoglycosides to other epithelia, especially to the lung, appears to merit further investigation.  
 
In summary, the extent and rate of tobramycin absorption, the existence of tissue binding and/or 
lung retention remains uncertain, especially from the kinetic and mechanistic aspects, in part 
because of the difficulties of studying pulmonary disposition in animals and humans. Since a 
solute’s physicochemical properties affect its penetration through the pulmonary barrier (Patton et 
al., 2004), an understanding of tobramycin’s molecular characteristics is important. Tobramycin 
is an aminoglycoside with a relatively large molecular weight (MW=467.5 Da). The structure of 
this compound (Figure I.1) consists of an aminocyclitol connected to two amino sugars by 
glycosidic bonds. There are 5 amino groups in the structure and the pKas shown in Figure I.1 are 
as reported by Szilagj et al.(1993); these amino groups will be predominately ionized and the drug 
should carry about 2.5-3 positive charges based on the reported pKa values under physiological 
conditions (pH7.4). The predicted LogP (logarithm of the partition coefficient between octanol 
and water for the neutral form) and LogD (pH 7.4) (logarithm of the distribution coefficient 
between octanol and water at pH7.4) were reported to be  -4.224 and -9.54, respectively, indicating 
the drug’s extreme hydrophilicity and how this is enhanced by protonation of the amino groups 
(LogP and LogD prediction were performed by ACD/PhysChem Suite (Advanced Chemistry 
Development, Inc., Toronto, Canada), a software used for prediction of physicochemical 
properties).  
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Figure I.1 Tobramycin chemical structure and pKa values 
 
Solute absorption from the airways of the lung is generally believed to occur via diffusion 
and/or partitioning (Brown and Schanker, 1983). For hydrophilic solutes, passive diffusion is 
expected via paracellular tight junctions between epithelial cells as the primary pathway through 
pulmonary barrier, due to the difficulties that such solutes experience in penetrating into the 
phospholipid bilayers in epithelial cell membranes (Brown and Schanker, 1983; Effros and Mason, 
1983; Schanker and Less, 1977; Schneeberger, 1991). The absorption of lipophilic solutes, to the 
contrary, occurs by transcellular diffusion/partition, and correlates with molecular partition 
coefficients between octanol and water (Brown and Schanker, 1983). The absorption of lipophilic 
compounds is generally faster than that of hydrophilic ones, given a similar range of molecular 
size (Brown and Schanker, 1983), since the surface area of the epithelial cell membranes in the 
pKa 8.9 
pKa 8.3 
pKa 5.7 
pKa  7.1 
pKa 7.8 
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lung, available for transcellular diffusion, is much larger than that for intercellular or paracellular 
diffusion via tight junctions between cells. 
 
Tight junctions are known as a complex belt-like network of strands and fibrils which are 
polymers of interacting transmembrane proteins and lipids (Su and Sheppard, 2008);  they are 
believed to represent relatively impermeable structures in which “aqueous pores” reside (Sakagami, 
2000). These pores may alternate between open and closed configurations as channels for solute 
transport (Claude, 1978; Reuss et al., 1991). These hypothetical “pores” with various sizes in the 
pulmonary epithelium were demonstrated in several studies by Schanker and coworkers (Enna and 
Schanker, 1972; Lin and Schanker, 1983; Schanker and Hemberger, 1983). In those studies, the in 
vivo disappearance rates of miscellaneous hydrophilic compounds from the lungs were determined 
by quantifying the dose remaining in the lungs at various time points following intra-tracheal 
instillation or aerosol inhalation in anesthetized animals (Brown and Schanker, 1983; Enna and 
Schanker, 1972). Notably, the absorption of a series of non-metabolized and lipid-insoluble 
saccharides, with similarities to aminoglycosides in structure and metabolic properties (non-
metabolized in lung), were also investigated by Schanker’s group (Enna and Schanker, 1972). The 
absorption of these saccharides appeared to be dose-independent with the first-order absorption 
rate constants, ka, ranging from 0.025-10.4 h-1 and where ka values were inversely related to 
molecular weight. The mean absorption half life of mannitol (MW=182 Da), sucrose (MW=342 
Da) and inulin (MW=5,250 Da) in rat lungs were reported to be 65, 87, and 225 minutes 
respectively. In their study, passive paracellular diffusion (via tight junctions) was concluded as 
the pathway for these saccharides’ absorption from the airways into the blood, because both the 
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extent and rate constants for absorption were dose- and concentration-independent (Enna and 
Schanker, 1972).  
 
Clearly, mechanisms other than diffusion and partitioning, such as transporter-mediated 
absorption or vesicle-mediated endocytosis and transcytosis, may be involved in solute absorption 
from the airways (Patton et al., 2004). In a recent review of drug transporters in the lung, the 
expression and potential impact of transporters (such as P-glycoprotein, P-gp, and organic cation 
and organic anion transporters, OCT and OAT, etc.) were described in detail (Bosquillon, 2010).  
At this time however, there is no strong evidence to indicate the involvement of transporters in the 
absorption of drugs delivered to the lung (Bosquillon, 2010). Similarly, our knowledge of 
pulmonary absorption by vesicle mediated endocytosis and transcytosis is limited and mostly 
associated with macromolecules (Patton, 1996).   
 
In general, solute disposition in the lung following inhalation is a complex function of regional 
deposition, mucociliary clearance, active and/or passive absorption, tissue sequestration and 
metabolism (Byron et al., 1994; Niven et al., 1990). Unfortunately, the kinetics and mechanisms 
describing the behavior of individual solutes remain largely theoretical, due to the lack of 
appropriate experimental systems for characterization of these processes. In vivo studies in animals, 
combined with intratracheal instillation or aerosol administration, have been applied to 
characterize solute absorption rate and extent following airway administration in Schanker and 
others’ laboratories (Brown and Schanker, 1983; Sakagami et al., 2003). While such methods 
enable the direct assessment of drug pharmacokinetics in vivo, reproducible airway dosing and 
considerable animal sacrifice are necessary (large numbers are required) to reduce the inter-animal 
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variations in whole body clearance that make characterization of absorption and disposition 
possible (Sakagami, 2006).  
 
More recently, reconstructed lung epithelium, cultured from human lung adenocarcinoma cell 
lines or primary cultured alveolar epithelial cells, have been used to clarify the kinetics and 
mechanisms of solute transepithelial transport in vitro (Sakagami, 2006). The convenience and 
low cost of cell culture are potentially great advantages, when these methods are compared to the 
use of whole animals. Unfortunately, the variables associated with lung cell isolation and culture 
and a lack of standardization create uncertainties so that results between laboratories from similarly 
cultured cells are rarely comparable (Sakagami, 2006). Moreover, the relevance of using these 
reconstructed barriers to represent complex intact lung is still debatable. For these reasons, the ex 
vivo model of the isolated perfused lung appears to resolve some deficiencies in both these in vivo 
and in vitro methods; it also offers a great alternative for the study of lung-specific 
pharmacokinetics, by virtue of its well-maintained structural and functional integrity and the 
absence of the whole body complication introduced by solute distribution and elimination in vivo 
(Sakagami, 2006). The ex vivo method provides advantages, such as enabling relatively accurate 
and reproducible drug administration to the airways, convenient sampling of perfusate and lavage 
fluids, and easy determination of mass balance (Tronde et al., 2003). Hence, this model has found 
use for investigations of absorption, tissue sequestration, metabolism and mucociliary clearance.  
The isolated perfused rat lung (IPRL) preparation described by Byron and Niven, that combined 
with a highly reproducible “forced intratracheal instillation” technique for solute administration 
into the airways, brought great improvements to the accurate and precise determination of 
absorption rate and extent (Byron and Niven, 1988; Byron et al., 1986). In part because the IPRL 
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preparation is studied in a physiological normal orientation (horizontally suspended) with a 
horizontally exteriorized trachea cannula, the preparation has found its way into text books as a 
way of studying aerosol deposition (Byron et al., 1986; Sinko, 2006). The method has also been 
employed successfully in many studies to address issues regarding the kinetics and mechanisms 
of solute absorption and disposition following airway administration in a number of different 
academic groups (Byron et al., 1994; Niven and Byron, 1990; Niven et al., 1990; Pang et al., 2005; 
Sakagami et al., 2002).  
 
The use of the IPRL preparation for the study of solute binding and/or sequestration after airway 
administration is yet to be described. The affinity and capacity of solute tissue binding has largely 
been investigated in vitro using equilibrium dialysis with tissue homogenates or slices (Pacifici 
and Viani, 1992; Wilkinson et al., 1986). Clearly, structurally modified tissues are unlikely to 
behave like intact organs, and therefore results from in vitro equilibrium dialysis experiments fail 
to provide usable predictive information for solute tissue binding in vivo. In this thesis, an attempt 
has been made to improve the bio-relevance of an in vitro binding assay and to marry the results 
to those from the intact organ. The dialysis of sliced isolated lung tissues was performed 
immediately after drug administration to the airways, to gain more insight to the in vivo lung tissue 
binding of tobramycin by mimicking the environment in which the drug was administered.  
Dynamic dialysis under sink conditions was first described by Meyer and Guttman (Meyer and 
Guttman, 1968; 1970). The technique was modified in this dissertation to support the use of the 
IPRL preparation for the combined characterization of tobramycin’s lung tissue binding behavior 
and absorption. This method, initially applied for protein binding studies, has been used 
successfully by other groups to study solute-ligand binding, by virtue of its providing more kinetic 
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information than equilibrium dialysis alone (Farrell et al., 1971; Hashimoto et al., 1984; Leo et al., 
1999; Meyer and Guttman, 1968; Pedersen et al., 1977). 
 
This dissertation aims to enhance the understanding of pulmonary absorption and retention of 
tobramycin in the airways following inhalation by targeting and describing experiments designed 
to study the kinetics and mechanisms of absorption and disposition in the lung. In an attempt to 
elucidate the kinetics and extent of pulmonary absorption in humans, the systemic bioavailability 
of inhaled tobramycin in adults was re-evaluated by performing a meta-analysis of PK studies of 
aerosolized tobramycin using the available data in the literature. To explore the kinetics and 
mechanisms responsible for aerosolized tobramycin’s pulmonary disposition, the absorption and 
binding behavior of tobramycin was then assessed in the most realistic ex vivo model of the rat 
lung, the IPRL, as a function of dose and local concentration, using a previously described method 
to administer the drug reproducibly (Byron and Niven, 1988). The effect of pH and osmolality of 
dosing solutions was also investigated to eliminate possible secondary factors that may impact the 
drug’s absorption and disposition. By combining the IPRL preparation with dynamic dialysis, a 
disposition model for tobramycin binding and/or sequestration was developed and validated after 
drug administration to the airways. Based on the results from these binding experiments, a kinetic 
model for tobramycin absorption and disposition following airway administration in the IPRL was 
used to interpret and discuss the data from the IPRL. The findings in this study are discussed in 
the light of the literature concerning the lung’s interactions with inhaled compounds, perhaps to 
aid in the future development of drugs designed to target lung tissue.  
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Chapter II 
HYPOTHESES AND SPECIFIC AIMS 
 
 
 
The efficacy and safety brought about by administration of tobramycin via inhalation is well-
recognized for the treatment of lung infections in clinical circles (Chuchalin et al., 2009). However, 
it remains unclear whether the antibiotic’s physicochemical properties are such as to lead to slow 
absorption, tissue binding and/or lung retention to sustain the drug’s presence and antimicrobial 
properties for periods between dosing. This dissertation was aimed to enhance the understanding 
of tobramycin’s absorption from, and retention in, the airways and lung tissues, by targeting 
experiments designed to study the kinetics and mechanisms responsible for the drug’s disposition 
following airway administration. The central hypothesis was that tobramycin was slowly absorbed 
from airways to the blood following local delivery to the lung, primarily by passive diffusion via 
the paracellular pathway, due to its hydrophilic and polycationic properties at physiological pH 
(Szilagyi et al., 1993). Tobramycin’s bioavailability following airway administration, was 
presumed to be low, based on the reportedly poor permeability of aminoglycosides across 
gastrointestinal barriers seen following oral administration (Jaresko and Alexander, 1995; Phillips 
and Shannon, 1997). Because aminoglycosides and tobramycin have been shown to bind to tissues 
in kidney and inner ear to form “deep compartments” (French et al., 1981; Mingeot-Leclercq and 
Tulkens, 1999; Nagai and Takano, 2004; Schentag, 1978; Schentag et al., 1978; Stepanyan et al., 
2011), we also hypothesized that the drug could bind to lung tissue and that the degree of this 
binding could be dose- and/or concentration-dependent. Because of slow absorption, any retention 
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in the airways was thought likely to prolong the drug’s antimicrobial efficacy following local 
delivery. Finally, because these characteristics were believed to be due primarily to the drug’s 
physicochemical properties, we hypothesized that the drug’s formulation in dosing solutions with 
different osmolalities and small changes in pH were not likely to significantly affect its pulmonary 
disposition.  
  
The following Specific Aims were used to test these hypotheses: 
 
1. To estimate tobramycin’s pulmonary bioavailability following inhalation in humans 
using pharmacokinetic (PK) meta-analysis. Selected tobramycin blood level and sputum 
concentration data from CF and healthy adults were taken from the clinical literature and 
re-analyzed using non-compartmental and compartmental approaches to assess 
tobramycin’s pulmonary bioavailability. Both the rate and extent of absorption of the lung 
deposited dose was assessed. The available sputum PK data following inhalation were also 
systematically reviewed and discussed in the light of the earlier meta-analysis of blood 
level data. Specific Aim 1 is described in detail in this thesis in Chapter III. 
 
2. To characterize the kinetics and mechanisms of tobramycin’s disposition in the rat 
lung following administration to the airways and to build a kinetic model to describe 
the results.  
 
a) To assess tobramycin disposition in rat lungs using a realistic ex vivo model, the isolated 
perfused rat lung preparation or IPRL. Tobramycin disposition in the rat lung following 
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airway administration was studied as a function of dose and local concentration using a 
previously described method (Byron and Niven, 1988). To explore the kinetics and 
mechanisms of the drug’s absorption from the airways, the mean cumulative absorbed 
fraction of each administered dose absorbed into the perfusate, Fp, was compared to that of 
the absorption markers, fluorescein (known for its rapid and complete absorption) and 
mannitol (known for its paracellular absorption), as a function of time following 
administration. To support the development of a disposition model with the presence of 
drug binding and/or sequestration to the lung tissues, dynamic dialysis of sliced IPRL 
tissues was studied immediately after drug administration to the airways, to assess the 
binding or tissue sequestration properties of tobramycin.  These experiments and the 
resultant kinetic model for tobramycin absorption and disposition in the IPRL are described 
in detail in this thesis in Chapter IV. 
 
b) To investigate the effects of osmolality and pH of dosing solutions on tobramycin’s 
absorption from the airways of the IPRL. The potential airways’ anatomical and 
functional alteration due to the administration of non-isotonic and non-physiologic pH 
solutions to the airways has been reported  to alter solute transport through the airways 
(Beasley et al., 1988; Eschenbacher et al., 1984; Glauser et al., 1979; Schanker and Less, 
1977). In the literature, the osmolality of tobramycin dosing solutions appears to be 
theoretically unpredictable (Law, 2001) in that measurements have indicated much smaller 
osmolality values than those based on theoretical calculations. Therefore, in some 
experiments, in which absorption from the airways of the IPRL was studied, the osmolality 
of dosing solutions was measured experimentally while in others, the effects of varying the 
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concentration of NaCl (0.225-0.9% w/v) and/or the pH of the dosing solutions (tobramycin 
concentration held constant) was assessed.  
 
 
c) To evaluate the effect of tobramycin on airway epithelial integrity in the IPRL. Because 
aminoglycosides and other polycations in certain concentration ranges have been reported 
to affect epithelial integrity and/or alter solute permeation through epithelia in vitro and in 
vivo (Dong et al., 2011; Todd et al., 1994), the effect of tobramycin on mannitol absorption 
from the airways of the IPRL was investigated following co-administration of mannitol 
with tobramycin at different concentrations to the airways. Because mannitol is accepted 
as a marker solute for paracellular absorption through different epithelia, the approach was 
used to elucidate whether the tobramycin itself could increase its own permeability at high 
drug concentrations by affecting the airway epithelial integrity. 
 
In summary, the work described in thesis Chapters III and IV focus on the evaluation of 
tobramycin’s absorption and retention following airway administration in humans and rats, 
respectively. These culminate in Chapter IV, where a disposition model is described that invokes 
dose and concentration-dependent drug binding and/or sequestration to lung tissues to explain the 
kinetic handling of tobramycin by the rat lung. Chapter V is aimed to validate and place constraints 
on that disposition model by describing the results of experiments designed to eliminate the 
possibilities that perturbations other than tissue binding or sequestration may have been 
responsible for some of the effects predicted at concentrations likely to be seen following 
inhalation.  
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Chapter III * 
PHARMACOKINETIC META-ANALYSIS TO ESTIMATE TOBRAMYCIN’S 
PULMONARY BIOAVAILABILITY FOLLOWING INHALATION IN HUMANS 
 
 
 
III.a  INTRODUCTION 
 
Inhaled tobramycin is recommended for the maintenance treatment of lung infections 
associated with Pseudomonas aeruginosa in cystic fibrosis (CF) patients, as an alternative to 
intravenous (IV) administration, in order to deliver high antibiotic concentrations direct to the site 
of infection while minimizing the drug’s systemic toxicity (Cheer et al., 2003; Geller et al., 2002; 
Touw et al., 1995).  Although its efficacy and safety are well-recognized, tobramycin’s pulmonary 
biopharmaceutics are not well understood in humans, partly due to the general technical difficulties 
involved with (a) characterizing the true dose administered to the lungs by different pulmonary 
delivery systems in the clinic and (b) the analytical challenges associated with determining the low 
blood levels of tobramycin resulting from inhalation (McGlinchey et al., 2008; Pechere and Dugal, 
1979).  
 
Notably, there are no published studies in which tobramycin’s pulmonary bioavailable fraction, 
F, of the total lung deposited dose (TLD) has been determined and none in which an IV reference 
experiment has been performed in the same subjects. In CF patients, absorption has been estimated 
*Some of this chapter has been published in Li and Byron (2012) 
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with reference either to nominal loaded doses placed in the delivery devices (e.g. ampoule label 
claims added to nebulizer reservoirs) or the in vitro emitted doses from the chosen delivery system 
(e.g. apparent output from a powder inhaler after the use by subjects) (Cooney et al., 1994; Geller 
et al., 2002; Touw et al., 1997). Not surprisingly, pulmonary bioavailability estimates with no 
consideration of the true doses delivered to the lung, show large variations across the literature, 
due to the high variability in delivery efficiency of inhalation devices for different formulations, 
as well as inter-individual variations associated with breathing patterns, respiratory physiology and 
function, and the drug’s variant pharmacokinetics that are seen in CF patients. 
 
In humans, aminoglycosides are neither plasma protein bound nor metabolized, and are mainly 
distributed through the body’s extracellular compartments; excretion of the unchanged drug in 
urine occurs via glomerular filtration with a small percentage of the filtered fraction reabsorbed by 
the renal proximal tubules (Pechere and Dugal, 1979). Systemic bioavailability of this class of 
drugs from the GI tract is very low, since the drugs’ blood levels concentration was reported to be 
extremely low following oral administration (Jaresko and Alexander, 1995; Phillips and Shannon, 
1997; Weber et al., 1995). Drug accumulation or tissue sequestration has been documented in the 
labyrinth of the inner ear and the renal cortex of the kidney after IV administration; this is believed 
to cause the ototoxicity and nephrotoxicity associated with most aminoglycosides (Selimoglu, 
2007; Todd and Hottendorf, 1995). To deal with the toxicity of aminoglycosides, in 
pharmacokinetic studies, a 3-compartment model has often been used that contains a so-called 
“deep compartment”, responsible for drug accumulation or tissue sequestration (French et al., 1981; 
Schentag, 1978; Schentag et al., 1978). However, the slow phase of elimination (γ), that is 
associated with this deep compartment, was generally not easy to characterize, as it appeared about 
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24 hours following IV administration with a half live of a few days, and there were analytical 
difficulties assaying extremely low drug concentrations in these circumstances. In clinical practice, 
after a single dose, the 2-compartment open body model, in which the rapid distribution phase 
corresponds to fast distribution through fluid compartments and elimination occurs via renal 
excretion, is generally sufficient to describe tobramycin disposition after IV administration 
(Aminimanizani et al., 2002; Inclan et al., 2005).  
 
In CF patients, aminoglycosides are generally believed to show different intrinsic 
pharmacokinetic behavior to that seen in non-CF humans, with an increased total body clearance 
(CL) and/or a larger volume of distribution (Vd) (Horrevorts et al., 1988; Levy et al., 1984). Larger 
inter-subject variability in PK parameters, was also often seen in CF in comparison to non-CF 
patients, probably because of the disease physiological and pathological complex (Mauro et al., 
1995; Town et al., 1996). From the point of view of aerosol delivery moreover, CF patients are 
generally known to have mucus build-up in the airways and decreased mucociliary clearance, 
because of the abnormal chloride ion secretion in the respiratory tract caused by reduced or absent 
function of the cystic fibrosis transmembrane conductance regulator (CFTR) (Donaldson et al., 
2007). Overall, these factors in CF may contribute to further variability in tobramycin pulmonary 
bioavailability following inhalation. 
 
In this chapter, a meta-analysis is described that was performed using literature data to assess 
tobramycin’s pulmonary bioavailability (the rate and extent of absorption of the lung deposited 
dose) separately in CF and healthy adults. This meta-analysis combined the inhalation PK data in 
which lung dose determinations were performed with tobramycin’s IV data from the literature. 
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These PK data were re-evaluated by non-compartmental and compartmental approaches to assess 
the pulmonary bioavailable fraction (F) and the apparent first-order absorption rate constant 
following inhalation. In the effort to evaluate the absorption kinetics, the time-course of 
tobramycin blood concentration profiles following inhalation were re-analyzed by deconvolution, 
using the Loo-Riegelman method (Gibaldi and Perrier, 1975). This method is known as a very 
useful and rigorous method for the evaluation of absorption kinetics that applies generally to linear 
multi-compartment PK models (Gibaldi and Perrier, 1975)  and is one that has been used 
successfully in inhalation work when dealing with experimental data (Clark and Byron, 1986).  
 
Following aerosol delivery and deposition in the lung, in the case that drug biological 
transformation and degradation are absent in the lung, the converse of absorption is, of course, 
drug retention in the airways. It is notable therefore, that tobramycin lung retention following 
inhalation, should favor its antipseudomonal efficacy, and be a subject of interest to those studying 
its clinical pharmacology and aerosol development (Patton et al., 2004; Ruddy et al., 2013).  It is 
hardly surprising therefore, that the sputum concentration of tobramycin following inhalation in 
CF patients has been extensively investigated in many studies to assess the drug’s in vivo local 
antibacterial activity, the apparent delivery efficiency of various inhalation devices, and even 
tobramycin’s potential accumulation in the lung with repeated administration (Eisenberg et al., 
1997; Geller et al., 2003; Poli et al., 2007; Ruddy et al., 2013). The topic is complicated by the 
difficulty in obtaining sputum samples for analysis that are in some way “representative” of the 
drug’s “non-absorption” following delivery to different sites on an enormous epithelial surface. In 
general therefore, there is high variability seen in tobramycin sputum concentrations following 
inhalation, and it makes the results difficult to interpret.  These variations are attributed to the 
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different delivery efficiencies of devices, the time and methods to collect airway secretion samples, 
and the human subject’s disease status and airway anatomy (Gibson et al., 2003). Nevertheless, to 
gain more insight into drug retention in the airways, the available sputum PK data following 
inhalation are systematically reviewed and discussed, in an attempt to add this information to the 
meta-analysis. These data are not available for healthy humans in the literature and therefore, only 
studies in CF patients were included in this analysis.  
 
III.b  METHODS 
 
     Pulmonary bioavailability 
     Tobramycin PK studies after IV and inhalation administration were systematically retrieved by 
subject searching for “tobramycin pharmacokinetics” in PubMed (1968-2013 July) and manually 
adding articles retrieved from the reference sections of key articles obtained from that PubMed 
search. Studies were selected for analysis if they met the following Eligibility criteria: 
1. Tobramycin PK data from adult CF or adult healthy humans with ages between 17 and 65 
years old were included if the drug was administered either intravenously or by inhalation 
and drug blood concentrations were determined for at least 5 time points after 
administration (for IV studies, the sampling duration covered both distribution and 
elimination phases, while for inhalation studies the sampling duration spanned both 
absorption and elimination phases). 
2. Impaired renal functions or critical illness were excluded to avoid unexpected changes in 
clearance under these conditions (Leroy et al., 1978; Pechere and Dugal, 1976). Abnormal 
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renal function was defined as creatinine clearance out of the normal range 80-160 
ml/min/1.73 m2. 
3. Research studies involving inhalation were selected only if the lung dose determination 
could be assessed with confidence from the article in question.  
4. Articles which failed to indicate that blood concentrations were greater than the reported 
assay lowest limit of quantitation (LLOQ) were rejected as were those in which blood level 
data were reported with sparse sampling schedules, such as those from routine therapeutic 
drug monitoring using peak and trough levels.  
The eligible data were categorized into CF and healthy groups, and analyzed separately by three 
different methods to assess the rate and extent of tobramycin absorption following inhalation.  
 
Method 1: This was a non-compartmental approach. The value of the fraction of the lung dose 
that was absorbed at time infinity, F, was estimated from:  
                                               F= CL/(TLD/AUCinh)                         eq. III.1 
where AUCinh is the total area under the drug blood concentration versus time curve following 
inhalation, CL is total body clearance and TLD is total lung dose; values for AUCinh were used 
either as reported in the literature, or they were calculated trapezoidally. AUC values from the 
ultimate concentration value (Clast) through time infinity were estimated from Clast/k where k was 
the negative log-linear slope of the concentration versus time data collected during the elimination 
phase in the inhaled drug study. The values of CL, for CF and healthy subjects, were obtained 
separately by averaging the pooled data from the eligible IV studies in each population across the 
literature, by taking the sum of the reported mean values for CL multiplied by the number of 
subjects in each study and finally dividing by the total number of subjects across all studies. The 
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mean (±SD where available) values of CL in each IV study was used as reported or in the event 
that it was not reported, calculated from CL=β*Vβ or dose/ܣܷܥஶ	and expressed per kg body 
weight; β, Vβ and ܣܷܥஶ	 refer to the terminal first-order, whole body elimination rate constant, 
the apparent volume of distribution and the total area under the concentration versus time curve 
following IV administration from time zero to infinity, respectively; the values of the PK 
parameters such as β, Vβ and ܣܷܥஶ	, were used as reported.   
 
Method 2: This was based on curve fitting of the inhalation data to equations representing the 
compartmental model shown in Scheme III.1. In this case, F with respect to the known value for 
TLD was given by ka/(ka+knal), the ratio of the first-order absorption rate constant (ka) to the total 
first-order rate constant for removal of drug from the lung following inhalation (equal to the sum 
of ka and knal, where knal is the first-order rate constant responsible for non-absorptive loss). A 2-
compartment PK model was chosen to analyze both the IV and inhalation data, because that was 
reported to provide the best description for tobramycin disposition following systemic exposure in 
clinical trials (Aminimanizani et al., 2002; Inclan et al., 2005). The PK parameters ݇௖௣	and ݇௣௖ are 
the apparent first-order intercompartmental transfer rate constants, ݇௘௟ is the apparent first-order 
elimination rate constant from the central compartment, and Vc is the apparent volume of the 
central compartment. The values of kcp, kpc, kel and Vc for CF and healthy subjects were derived 
separately from the IV data for each population. In short, the blood level versus time curves from 
these IV studies were digitally copied and the concentration data at each time point extracted using 
DataThief II (http://datathief.org), a graph reading java software and dose- and body weight- 
normalized where necessary. Curve fitting of the IV data was then performed in accord with a 2-
compartment PK model using non-linear regression and SCIENTIST® 3.0 (MicroMath, Saint 
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Louis, MO), to provide best estimates for kcp, kpc, kel and Vc. Similarly, non-linear regression was 
then employed to analyze the inhalation data in accord with Scheme III.1, where the values of kcp, 
kpc, kel and Vc were held constant at the best estimates obtained from the IV data. TLD was fixed 
at its reported value while ka and knal were allowed to float to produce the best curve fits of the 
inhaled blood level versus time data, plus best estimates for ka and knal and F.  
 
 
Scheme III.1 Pharmacokinetic model describing pulmonary clearance, absorption, distribution and 
elimination of the inhaled tobramycin total lung dose, TLD. First-order rate constants ka, knal, kpc, 
kcp, and kel represent absorption into the central sampled compartment with apparent volume Vc, 
non-absorptive loss from the lung, distribution between the central and peripheral compartment 
with apparent volume Vp, and elimination, respectively.  
 
Method 3: The Loo-Riegelman method (Gibaldi and Perrier, 1975) was used to assess the 
absorption properties of tobramycin following inhalation; the intrinsic PK parameters of this two-
compartment open body model drug were determined in CF and healthy subjects as described 
above (Method 2). The percent of TLD absorbed at time t, abs%, was then calculated by eq. III. 
2-5 calculated (Gibaldi and Perrier, 1975): 
                           ܾܽݏ% ൌ ஺ሺ೟ሻ஺ಮ ൈ 100%                                                                               eq. III.2 
Lung 
Central 
Compartment 
Vc 
Peripheral   
Compartment 
Vp 
ka 
kcp 
kpc 
kel knal 
   TLD 
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where           	ܣሺ௧ሻ ൌ ஼ܸܥ௉ ൅ ܣ௉ሺ௧ሻ ൅ ஼ܸ݇ଵ଴ܣܷܥ଴ି௧	                                                          eq. III.3 
	ܣ௉ሺ௧ሻ ൌ ܣ௉ሺ௧భሻ݁ି௞మభ∆௧ ൅
௞భమ஺಴	ሺ೟భሻ൫ଵି௘ೖమభ∆೟൯
௞మభ ൅ ݇ଵଶ ஼ܸሺ
∆஼೛
∆௧ ሻሺ݁ି௞మభ∆௧ ൅ ݇ଶଵ∆ݐ െ 1ሻ/݇ଶଵଶ      eq. III.4 
and ܣஶ ൌ 	 ௖ܸ݇ଵ଴ܣܷܥஶ	                                                                                                       eq. III.5 
where	ܣሺ௧ሻ and ܣஶ are the amount of drug absorbed systemically at time t, and the amount of drug 
that is ultimately absorbed, respectively; ܣ௉ሺ௧భሻand 	ܣ௉ሺ௧ሻ, are the amounts of drug in the peripheral 
compartment at the time of the first of any two consecutive sampling periods (i.e. t = t1) and at 
time t, while ܣ஼	ሺ௧భሻ is the amount of drug in the central compartment at the time of the first of the 
sampling period;	ܣܷܥ଴ି௧ and ܣܷܥஶ	are the area under the plasma concentration versus time curve 
from time zero to time t, and from time zero to infinity, respectively; ܥ௉  is the drug plasma 
concentration at time t and ∆ܥ௉	is the change of ܥ௉ in each period of time, ∆ݐ ൌ ݐ െ ݐଵ. 
 
The percentage remaining unabsorbed (100 - abs%) versus time plots were generated and used to 
predict the absorption rate constant for tobramycin after administration to the airways, assuming 
that absorption occurred only via the lung.  
     
Sputum pharmacokinetics  
Tobramycin concentrations in sputum sampled from adults and children (Ages ≥6 years) with 
CF after single or repeated inhalation doses were obtained from the systematic literature review 
described above. The subset of articles that were used for a review of sputum concentrations 
included those by Griese et al., 2013, etc. shown in Table III.4. To evaluate the variability 
associated with different study designs and methods, the drug formulations and delivery devices 
for inhalation, and the dosing and sampling regimens in these studies were tabulated and 
summarized. The values of  C௣௘௔௞௦௣௨௧௨௠, the “peak” sputum concentration, generally determined from 
samples taken 10-60 minutes post administration, and C௧௥௢௨௚௛௦௣௨௧௨௠, the pre-dosing level, as well as 
ܣܷܥ଴ି௧௦௣௨௧௨௠, area under the tobramycin sputum concentration time curve, immediately after dosing 
to the last sample time point (8 or 12 h), were compared across these studies to evaluate the 
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evidence for potential lung retention and/or accumulation of tobramycin in sputum after repeated 
inhalations. 
 
III.c  RESULTS AND DISCUSSION 
 
Pulmonary bioavailability  
A total of 633 papers were obtained from the keyword search in PubMed. Of these, only 18 
studies satisfied the Eligibility criteria for meta-analysis to determine tobramycin’s pulmonary 
bioavailability. The eligible studies included 15 IV PK studies in adult humans. IV studies were 
categorized into 2 groups: CF (6 studies) and Healthy (9 studies).  For the inhalation PK studies, 
two studies that met the Eligibility criteria were included: Pilcer et al. 2008 (in CF adults) and 
Newhouse et al. 2003 (in healthy adult volunteers), while a similar study by Lenney et al. was 
excluded from the meta-analysis because of the data insufficiency in this paper for the estimation 
of F or the absorption rate constants by Method 1, 2 and 3 (Lenney et al., 2011). In the inhalation 
studies, the lung doses were estimated using γ-scintigraphic imaging to characterize the deposited 
dose in the lung, after labeling formulations with 99mTc before administration (Newhouse et al., 
2003; Pilcer et al., 2008)   
 
Method 1 
The weighted mean value for tobramycin total body clearance (CL) was 1.88 ml/min/kg in CF 
adults, obtained from a total of 50 subjects in six IV PK studies, and 1.23 ml/min/kg in healthy 
adults, from a total of 80 subjects in nine IV studies. The individual reports and values are 
summarized in Table III.1. These clearance values are believed to be typical in these populations 
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and are consistent with excretion that occurs primarily via glomerular filtration. Notably, in the IV 
studies, values of CL for CF patients were generally larger than those for healthy subjects, although 
substantial variations were associated with both populations. The relatively larger values seen in 
CF were consistent with the findings of many other studies, in which an increased volume of 
distribution and CL were seen in CF (de Groot and Smith, 1987; Levy et al., 1984). The reasons  
for this PK change in CF patients remain unclear;  enhanced renal clearance, diminished tubular 
reabsorption or an additional alternative route of excretion such as respiratory or gastrointestinal 
elimination in CF have all been mentioned (Horrevorts et al., 1985; Levy et al., 1984). 
 
For CF patients in Pilcer’s study (2008), using the values of CL obtained from IV studies, the 
average estimates of F for 3 formulations administered in different doses, were 1.03 (lipid-coated 
dry powder), 1.09 (uncoated dry powder), and 1.70 (nebulized TOBI®) (Table III.2). The 
unrealistically high absorbed fraction, F >> 1 for the aqueous TOBI® formulation, delivered by a 
hand-held PARI LC Star nebulizer (PARI GmbII; Starnberg, Germany), could have been due to 
either the choice of an inappropriate CL value for Pilcer’s patients (Table III.1) or an experimental 
underestimated TLD assessment by Pilcer et al. (2008). The inaccuracy in the case of TOBI® may 
also indicate that values of F from Pilcer’s powder formulations, delivered by the 
aerolizer® (Novartis, Switzerland), are also unreliable (Table III.2). 
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Table III.1 Total body clearance values for tobramycin reported or calculated from IV PK 
studies in CF and normal human adults 
 
CF Healthy 
Ref n CL* (ml/min/kg ) Ref n 
CL* 
(ml/min/kg )
Butterfield 2013 9 1.2±0.2 Champoux 1996 12 1.3 
Moriarty 2007 14 1.6 Mauro 1995 8 1.2±0.1 
Aminimanizani 2002 6 2.0 Woodworth 1994 6 1.2±0.1 
Bates 1997 8 1.4±0.4 Pleasants 1988 15 1.4 
Cooney 1994 6 2.5±0.3 Guglielmo 1987 8 1.3±0.2 
Horrevorts 1985 7 3.1±0.9 Winslade 1987 11 1.2±0.4 
   Pcherere 1976 4 0.8 
   Lode 1975 12 0.9 
   Regamey 1973 4 1.8±0.1 
Total 50 1.88** Total 80 1.23** 
* mean (±SD where available) as quoted or calculated (CL=β*Vβ or dose/AUC∞) and 
normalized for reported body weight; ** weighted mean by sample size from each study. 
 
Method 2 
The compartmental curve fitting approach, advocated by Sakagami (Sakagami, 2004) to 
determine the absorption of drugs following inhalation, also relied on the accurate assessment of 
intrinsic PK parameters determined from IV data in a different subject cohort; however values of 
F >>1 cannot be obtained using this method (Scheme III.1). In this case, two of the previously 
selected IV studies: Aminimanizani et al. (2002, for CF adults) and Pleasants et al. (1988, for 
healthy adults) were selected for analysis, mainly because (a) those two studies showed most 
frequent sampling over a sufficient length of time (more than 8 hours) following IV administration 
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and (b) the assay methods were believed to be reliable (Aminimanizani et al., 2002; Pleasants et 
al., 1988). The assay methods, fluorescence polarization immunoassay (TDX; Abbott Laboratories, 
Irving, TX), used in those two studies, were judged to be sensitive, accurate, precise and 
reproducible, compared to other analytical methods, such as enzyme-multiplied immunoassay 
(EMIT), radioenzymatic assays and microbiological assays used by others (Cheng et al., 1987; 
Touw et al., 1996). Best estimates of Vc, kcp, kpc, and kel for the IV data in Aminimanzani et al. and 
Pleasants et al. obtained using non-linear regression in accord with 2-compartment open model are 
shown in Table III.3 alongside values for the model selection criterion, MSC, and coefficient of 
determination, COD, both of which indicated excellent fits to the data. 
 
Table III.2 Values for F from analysis of inhalation PK data for tobramycin by Methods 1 and 2 
  
Lung deposited 
dose(mg)/% of 
nominal 
F 
Method 1 Method 2a 
Pilcer 2008  (CF) 
Lipid-coated powder from DPI 12.6/53.0% 1.03 0.99 
Uncoated powder from DPI 8.5/34.1% 1.09 NE 
TOBI® (PARI LC Star) 22.8/7.6% 1.70 NE 
Newhouse 2003  (Normal) 
DPI 27/34.3% 0.83 0.85 
TOBI® (PARI LC PLUS) 15/5.0% 0.78 0.76 
a Values shown for curve fits in Figure III.2; 
NE = not estimated (data fit not possible with fixed PK; Table III.3) 
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Table III.3: Pharmacokinetic parameters estimated by curve fitting IV tobramycin blood 
level data to a 2-compartment open body model a 
 
Data Source 
(ref) Vc (L/kg) 
kcp 
(hr-1) 
kpc 
(hr-1) 
kel 
(hr-1) MSC 
b c  r2 
Aminimanizani 
2002 
0.178 
(0.033-0.208) d 
 
0.92 
(0.24-1.94) d 
 
1.00 
(0.53-3.16) d 
 
0.64 
(0.43-2.43) d 
 
4.1-6.5 0.996-0.999 
Pleasants 1988 0.125 (0.112-0.137) e 
1.28 
(0.75-1.91) e 
1.66 
(0.99-2.33) e 
0.65 
(0.55-0.75) e 4.8 0.998 
 
a Gibaldi and Perrier, 1975; b Model Selection Criterion; c coefficient of determination; d median 
value (range) of the best estimates from 6 individual blood drug concentration versus time curves; 
e best estimate (95% CI) from curve fitting the mean blood drug concentration versus time curve. 
 
In the study of Newhouse et al. in healthy volunteers, the PK data for a tobramycin dry powder 
(PulmoSphereTM formulation; PStob; Inhale Therapeutic Systems; San Carlos, CA) delivered from 
a passive dry powder inhaler, was also compared to those from a commercial nebulized tobramycin 
product TOBI® delivered by PARI LC Plus nebulizer (Newhouse et al., 2003). The values of F 
were 0.83 for the powder formulation and 0.78 for nebulized TOBI® (Table III.2). Despite these 
apparently “reasonable” estimates for F, the wide variation seen around the average value of CL 
(1.23; reported range 0.8 - 1.8 ml/min/kg) for normal subjects that were used to analyze these data 
(50 adults, Table III.1) did not inspire confidence in this assessment of tobramycin’s pulmonary 
bioavailability. Overall, the results of Method 1 were inconclusive with respect to F, largely 
because of uncertainty in values for CL. Even so, the data were indicative of substantial pulmonary 
absorption, in spite of the known poly-cationic state of this drug at physiologic pH (Szilagyi et al., 
1993). As expected (Weber et al., 1995), there was also little evidence seen for any contribution 
of GI absorption to tobramycin blood levels following pulmonary administration. 
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In the inhalation study for healthy subjects, the Newhouse data (Newhouse et al., 2003) showed 
good agreement with the PK model described in Scheme III.1, as shown in Figure III.1. The 
calculated F values are shown in the final column of Table III.2. The values of F in normal subjects 
for nebulized TOBI® and dry powder were 0.76 and 0.84, respectively, consistent with the values 
calculated by Method 1. The estimates for ka ranged 0.30 – 0.41 h-1 in normals, corresponding to 
absorption half lives 1.7-2.3 hours, close to that of technetium-99 m-labelled diethylene triamine 
pentaacetic acid (99mTc-DTPA), a hydrophilic solute with a similar molecule size as tobramycin 
and recognized as a paracellular absorption marker following aerosol administration in human 
(Bondesson et al., 2007; Coates and O'Brodovich, 1986). For CF patients in the study of Pilcer et 
al. (2008), however, the method failed to provide good fits to the inhalation data for the treatment 
groups using both nebulized TOBI® and the uncoated powder; plasma concentrations in Pilcer, 
that apparently resulted from the reported TLD, could not be reached in simulations with this 
model, even when very large ka values were employed.  It is possible that underestimation of TLD 
and/or variations in the drug’s intrinsic PK between patient cohorts were responsible for this 
apparent “failure” in curve fitting, but this also means that the estimate of F from Method 2 (= 
0.99, Table III.2) for Pilcer’s CF patients must also be viewed with suspicion, alongside the value 
for ka (= 1.0 h-1, Figure III.1). Notably, the possible underestimation of TLD in Pilcer’s study, 
discussed for Method 1, above, could also be the explanation for the results seen here, even though 
two quite different approaches were used for calculation. 
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Figure III.1 Mean tobramycin blood level versus time curves following inhalation; data from Pilcer 
et al.(2008)  and Newhouse et al.(2003). Best fits using nonlinear regression analysis to the PK 
model in Scheme III.1 according to Method 2 are shown as curves in which all rate constants other 
than ka and knal were held constant at the values shown in Table III.3. Pilcer data for formulations 
other than the lipid coated powder could not be fitted with the fixed rate constants shown in Table 
III.2 (NE in Table III.2). Estimates for the absorption rate constant ka were 1.00, 0.41 and 0.30 h-1 
for Pilcer (TOBI®), Newhouse (DPI) and Newhouse (TOBI®), respectively. 
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Method 3 
When the Loo-Riegelman method was used to analyze the data in the study of Newhouse et al. 
(2003) , the amount of bioavailable drug calculated for the nebulizer formulation TOBI® and the 
dry powder formulation was 12.2 mg (TLD=15 mg) and 26.1 mg (TLD=27 mg), corresponding to 
values for F = 0.82 and 0.97, respectively. These results were consistent with those from Methods 
1 and 2, indicating tobramycin’s pulmonary bioavailability as close to 100%. The percentages of 
drug remaining unabsorbed (100 - abs%) versus time plots (Figure III.2) in log-linear plots for 
both formulations indicated that tobramycin absorption from the lung appeared to be first-order. 
For Method 3 however, the absorption half lives fell in the range from 2.7-3.4 hours.  Pilcer’s data 
from CF patients for the nebulizer TOBI® could also be analyzed using this technique yielding the 
values for the bioavailable dose equal to 48.2 mg, more than two fold higher than the experimental 
determined lung deposited dose (22.8 mg) stated in the paper. For the lipid-coated and the uncoated 
drug powder formulation, the bioavailable doses were estimated at 15.3 mg and 11.4 mg, 
corresponding to 21 and 35% higher than the reported TLD for these two formulations, 
respectively. Clearly, these values for TLD, and the apparently non-linear absorption profiles in 
Figure III.2, for CF patients, were influenced significantly by the chosen estimates for the drug’s 
intrinsic PK parameters; those were derived entirely from the data of Aminimanizani et al. (2002), 
and they may well be unrepresentative of the behavior of tobramycin in Pilcer et al.’s patients. 
Notably however, given intrinsic PK parameters from selected IV experiments that are 
representative of a drug’s behavior following extravascular absorption, this approach (Method 3) 
may be an acceptable deconvolution method capable of determining independently, a value for the 
bioavailable dose. 
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Figure III.2 Semi-Log plot of percentages of bioavailable tobramycin remaining to be absorbed 
versus time following inhalation. Percentages of bioavailable tobramycin remaining to be 
absorbed were calculated for the inhalation formulations in the studies of Pilcer et al.(2008) and 
Newhouse et al.(2003)  by the Loo-Riegelman method (Gibaldi and Perrier, 1975). The apparent 
absorption half lives were 3.4 hr (nebulizer TOBI) and 2.7 hr (the DPI) for the data from healthy 
adults in the study of Newhouse et al.(2003), and 3.2, 3.3 and 3.4 hrs for the nebulizer TOBI, 
lipid-coated and uncoated DPI, respectively, in the study of Pilcer et al.(2008) on CF patients. 
 
 
Notably, tobramycin absorption data (the percentages of drug remaining unabsorbed (100 - 
abs%) versus time) from the CF patients in the study of Pilcer et al. (2008) showed a slight 
deviation from mono-exponential absorption kinetics, showing a suspected biphasic absorption 
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behavior. One explanation for this apparent biphasic absorption behavior may possibly be 
decreased mucociliary clearance caused by mucus build-up, often associated with CF patients 
(Donaldson et al., 2007). Alternatively, drug binding and/or sequestration in lung tissues, that tends 
to prolong the drug’s absorption after airway administration, may also be responsible for this 
biphasic absorption.  
 
Sputum pharmacokinetics 
Ten studies in CF patients were analyzed in an attempt to evaluate tobramycin concentration 
data in sputum following repetitive dosing by inhalation. Table III.4 shows the summary of sputum 
PK studies that were considered.  After inhalation of tobramycin solution (either 300 mg in 4 mL 
of ½ normal saline (1/2NS) or 300mg in 5 mL ¼ NS were delivered by nebulizer, the drug sputum 
concentration could exceed by more than 100 times the reported tobramycin minimum inhibitory 
concentrations (MICs) for Pseudomonas aeruginosa; MICs have been shown to vary between 0.5 
and 32 mg/L for isolates obtained from patients with cystic fibrosis treated with once- or thrice-
daily intravenous tobramycin while the MIC90 (MIC required to inhibit the growth of 90% of 
organisms) after inhalation treatment was reported as 16 mg/L (Burkhardt et al., 2006; LiPuma, 
2001). These high drug levels in sputum have been used in the literature to imply antimicrobial 
efficacy after local drug delivery to the lung.  
 
Despite the large variations between subjects, the mean or median C௣௘௔௞௦௣௨௧௨௠ and ܣܷܥ଴ି௧௦௣௨௧௨௠, 
were comparable between studies, given comparable formulations and delivery systems, e.g. 
TOBI® (300 mg/5mL in ¼ NS and pH 6.0) delivered by PARI LC PLUS® (Table III.4).  The 
eFlow® nebulizer was reported to achieve a higher C௣௘௔௞௦௣௨௧௨௠ than the PARI LC PLUS® in one study 
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(Hubert et al., 2009), while this conclusion was not reached by others (Govoni et al., 2013; Griese 
et al., 2013), possibly due to large inter-subject variations. The values of tobramycin sputum 
concentrations determined in the study of Griese et al.(Griese et al., 2013) were relatively higher 
than those of other studies using the same formulation and delivery system for unknown reasons, 
although the high variability seen in sputum concentrations appear to be due mostly to variable 
inhalation and deposition patterns, airway obstruction and anatomy differences seen with age and 
disease, mucus plugging, individual sputum production rates and the use of different assay 
methods for sputum samples (Hubert et al., 2009). 
 
Tobramycin retention and accumulation in the lung following inhalation were generally 
assessed by evaluation of the drug’s persistence after a single dose and the changes in “peak” and 
“trough” sputum concentrations, as well as ܣܷܥ଴ି௧௦௣௨௧௨௠ values after repeated dosing. Theoretically, 
the drug peak concentrations in sputum may behave most likely as a surrogate of initial deposition 
in the airways and could be very variable (Okubo and Iyobe, 2002). Drug trough concentrations in 
sputum determined pre-dosing (approximately 12 h following last inhalation) can probably better 
reflect the true concentrations in the lung, since drug deposited in the upper airways such as 
laryngopharynx and trachea can be removed by clearance and swallowing within a couple of hours. 
 
In general, tobramycin concentrations in sputum rapidly decreased 1-2 h after administration of 
TOBI® by PARI LC PLUS®, and then became undetectable 3 to 12 h after a single dose by 
inhalation, indicating rapid removal of this drug from the lung, by absorption into the systemic 
circulation, mucociliary clearance and swallowing. However, the values of trough tobramycin 
concentrations at steady state (pre-dose drug concentration in sputum at day 15 or day 28) after 
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twice daily dosing were reported to be 148±354 μg/g and 135±93 μg/g, by Hubert et al. in children 
and Govoni et al. in adults, respectively, implying that some drug accumulation occurred in the 
airways after repeated dosing, and not all of the administered dose is absorbed 12 hours after 
inhalation. Consistent with that data for escalated trough levels, tobramycin was found to 
accumulate 3.7-fold in the sputum with eFlow® and 2.1-fold with PARI LC PLUS®, shown by the 
ratio of sputum AUC0-8h between Day 15 and Day 1 in the study of Hubert et al. In contrast 
however, the study of Govoni, et al. reported tobramycin accumulation in sputum after 28 days’ 
dosing (twice daily) as “low”, because the ratios of C௣௘௔௞௦௣௨௧௨௠and ܣܷܥ଴ି଼௛௦௣௨௧௨௠ (geometric mean at 
1.06 for C௣௘௔௞௦௣௨௧௨௠ and 1.61 for ܣܷܥ଴ି଼௛௦௣௨௧௨௠) between Day 28 and Day 1 differed insignificantly 
from unity (Govoni et al., 2013). In Govoni et al.’s study however, the large inter-subject variations 
seen in sputum concentrations likely disguised the possible change in C௣௘௔௞௦௣௨௧௨௠ and ܣܷܥ଴ି଼௛௦௣௨௧௨௠, 
caused by repeated dosing (Govoni et al., 2013).  
 
In another study, tobramycin accumulation in the lung after 28 days’ repeated dosing (twice 
daily) by inhalation in CF patients was evaluated in children less than 6 years old, using tobramycin 
concentrations in epithelial lining fluid (ELF) collected by bronchoalveolar lavage (BAL) (Gibson 
et al., 2003). The drug concentrations in ELF are believed to be more representative of levels in 
the deep lungs, compared to drug concentration in the sputum sample (Tayman et al., 2011), 
although ELF is more difficult to collect and concentration data more difficult to interpret. 
Nevertheless, tobramycin was detectable in ELF an average 12 h after the last dose at Day 28, with 
a mean (±SD) concentration of 74 (±50) μg/mL (Gibson et al., 2003). Compared with the mean 
(±SD) drug concentrations of only 90 (±54) μg/mL in ELF at the “peak” level  (45 min after 
inhalation) and generally undetectable concentrations after 12 h after a single or first dose (Gibson 
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et al., 2003; Rosenfeld et al., 2001), these results clearly indicated drug accumulation in the lung 
after repeated doses. High trough drug levels in the ELF of young children at steady state, 
combined with the sputum results in CF patients in the studies of Govoni, et al. (2013) and Hubert 
et al.(2009), with ages ≥6 yrs, all support a finding of tobramycin retention and accumulation in 
respiratory secretions when repeated inhalation occurs in CF patients.  
 
  
39 
 
 
 
Table III.4 Summary of sputum pharmacokinetics for tobramycin following inhalation in CF 
patients.     
Ref  N1 
Age of 
subjects 
yrs 
Sputum 
sampling 
times(post
-dose) 
Device/ 
Formulation 
First day  Last day 
2 ܥ௣௘௔௞௦௣௨௧௨௠  
(mean±SD) 
ug/g 
3ܣܷܥ଴ି௧௦௣௨௧௨௠  
(mean±SD) 
μg*hr/g 
 2ܥ௣௘௔௞௦௣௨௧௨௠  
(mean±SD) 
μg/g 
3ܣܷܥ଴ି௧௦௣௨௧௨௠ 
(mean±SD) 
μg*hr/g 
Govoni  
2013 27 ≥18  
 0.5, 1.5, 3 
and 8 h on 
day 1 and 
day 28 
PARI eFlow® 
(300mg/4mL) 
540.8 
±676.5  529.4±714.4  
 
518.6±639.7  529.4±714.5  
PARI LC 
PLUS® 
(300mg/4mL) 
491.3 
±690.1  573.1±706.6  
 
819.9±1611.1  758.8±1470.4  
Griese 
2013 76 
average 
20  
10 min at 
day 7  
PARI eFlow® 
(150mg/1.5mL) NR ND 
4,82589 
(1967,3211)  ND 
PARI LC PLUS® 
(300mg/5mL) NR ND 
4,82272 
(1659,2885)  ND 
Ruddy 
2013 10 ≥10  
0.5-0.6 h 
on day 2 -
3  and day 
26-28 
PARI LC PLUS® 
(300mg/5mL) 
5 961.0 
(681.5,1.536)  ND 
51323 
(520,1730)   ND 
Hubert  
2009 25 ≥6  
0, 0.5,1.5, 
2 and 8 h 
on day 1 
and day 
15 
PARI eFlow® 
(300mg/5mL) 981±1191  1688±2046  
 
1572±2182 3731±7235  
PARI LC PLUS® 
(300mg/5mL) 754±927 1511±1744 
 
769±823 1941±2301 
Lenoir 
2007 21 ≥6 
0.5 h on 
day 1 and 
day 28 
PARI LC PLUS® 
(300mg/4mL) 
9 695.6±817.0  ND 
 
9 716.9±799  ND 
Poli 2007 11 18-37  0.5, 3, 6,12,24 h  
PARI LC PLUS® 
(300mg/4mL) 1289±851 NR 
 ND ND 
PARI LC PLUS® 
(300mg/5mL) 816±681 NR 
 ND ND 
Geller  
2007 84 ≥6 
0.5, 1, 2, 
4, 8 and 
12 h  
PARI LC PLUS® 
(300mg/5mL) 737±1028 974±1143  
  ND ND 
T-326 DPI 
(4*28mg) 1048±1080 1275±1359  
 ND ND 
Geller  
2003 49 15-36  
 0.2,1, 2,4 
and 8 h  
AeroDose® 5.5 
RP 
(90 mg/1.5 mL) 
959±952  1307±978  
 
ND ND 
PARI LC PLUS® 
(300mg/5mL) 985.7±839.3  1471±1278  
 ND ND 
Eisenberg 
1997 60 11-41  
 10 min, 1 
and 2 h  
UltraNeb 
(600mg/20mL) 
61359 
 (44-7782)  ND 
 ND ND 
Sidestream 
(300mg/5mL) 
6393  
(57-1998)  ND 
 ND ND 
PARI LC® 
(300mg/5mL) 
6452  
(47-3724)  ND 
 ND ND 
Weber  
1994 7 ≥7  
0.05, 1, 2, 
3, 4 h  
Pulmo-Aid 
(80mg/4mL) 
7325 (59-629)  NR 
 
ND ND 
NR: not reported; ND: not determined; 1 number of subjects; 2 the “peak” sputum concentration, 
generally determined from samples taken 10-60 minutes post administration; 3 area under 
concentration versus time curve for tobramycin in sputum determined trapezoidally in each study; 
t = the last time points for sputum determination; 4 mean (90%CI); 5 median (25th, 75th percentiles); 
6 median (range); 7 mean (range); 8 sputum concentrations determined on day 7; 9 concentration 
unit in μg/mL. 
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III. d  CONCLUSIONS 
 
In summary, the absorption of tobramycin from the lung appears to occur slowly but to be more 
complete than is commonly assumed based on the drug’s theoretical behavior as an 
aminoglycoside poly-cation at physiologic pH (Szilagyi et al., 1993). The large variance seen in 
published studies of tobramycin’s intrinsic pharmacokinetics (IV) precluded accurate assessment 
of its pulmonary bioavailability. A cross-over study, where drug plasma level versus time profiles 
are compared following IV and inhalation administration to the same subject cohort, is needed to 
eliminate the uncertainties associated with the evaluation of its fractional pulmonary absorption 
(F) in humans.  In CF patients, tobramycin absorption from the lung following inhalation appeared 
to occur more rapidly than in normals but this could not be stated with certainty from the drug’s 
pharmacokinetic data. The results from the sputum PK meta-analysis however, indicated that drug 
retention and accumulation in the lung following inhalation appeared to occur after repeated dosing, 
at least in CF patients. It was possible therefore, that some mechanism for tobramycin binding 
and/or sequestration was involved in extending the drug’s retention at the site of its action in 
humans. Further investigation into the kinetics and mechanisms of tobramycin disposition 
following airway administration in animals could thus be an alternative way to explore the drug’s 
binding and/or sequestration in lung tissues.    
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Chapter IV* 
TOBRAMYCIN DISPOSITION IN THE RAT LUNG FOLLOWING AIRWAY 
ADMINISTRATION 
 
 
 
IV.a  INTRODUCTION AND THEORY 
 
Administration of tobramycin directly to the airways via nebulizer has brought great 
improvements to the health and wellbeing of cystic fibrosis (CF) patients and others suffering from 
chronic pulmonary infections with pathogens such as Pseudomonas aeruginosa (Chuchalin et al., 
2009).The efficacy and safety brought about by topical use of this drug is well-recognized in 
clinical circles, although it remains unclear whether the antibiotic’s physicochemical properties 
lead to slow absorption, tissue binding and/or lung retention to sustain the drug’s anti-infective 
properties for periods between dosing (Li and Byron, 2012; Patton et al., 2004). Notably, 
tobramycin is believed to cross epithelial barriers poorly and it is therefore marketed primarily as 
an injectable (Jaresko and Alexander, 1995; Phillips and Shannon, 1997). Our recent meta-analysis 
of pharmacokinetic data in humans following IV and inhalation administration found that it was 
not possible to come to a statistically sound conclusion about its bioavailability and possible 
binding to, or sequestration in, lung tissue following inhalation administration due largely to the 
variance associated with the available data (Li and Byron, 2012), even though tobramycin and 
*The body of the text in this Chapter is reproduced (without the abstract) directly from the published work of 
the same title by Li M and Byron P.R. (2013) Journal of Pharmacology and Experimental Therapeutics 347: 
318-24. 
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other aminoglycoside antibiotics are known to manifest some of their toxicity through tissue 
binding or sequestration and the creation of “deep compartments” (Mingeot-Leclercq and Tulkens, 
1999; Nagai and Takano, 2004; Stepanyan et al., 2011). Notably, and probably because of the 
physiologic existence of these drugs as polycations, transfer into cells is slow and intracellular 
sequestration can be persistent. For these reasons we have used the isolated perfused rat lung (IPRL) 
to systematically investigate the disposition of tobramycin in the lung following its administration 
directly to the airways. The IPRL has been used similarly before (Byron et al., 1986; Niven and 
Byron, 1988; Niven et al., 1990; Sakagami et al., 2002). In the most simple cases, when solutes 
like fluorescein are administered in solution to the airways of this preparation, they behave in 
accord with Scheme IV.1. Absorption of fluorescein then occurs in a dose-independent, first-order 
fashion with no evidence of binding or metabolism. However, the nominal dose, or dose loaded 
into a dosing cartridge (Figure IV.1) usually results in a smaller administered dose (D) (Scheme 
IV.1), only part of which, the absorbable amount, A (A = D - U), where U is the transferable 
(unabsorbable) amount of each dose, can be transferred to the perfusate (P). This is because the 
bronchial circulation in the IPRL is severed and only solute that deposits proximal to the actively 
perfused pulmonary circulation can be absorbed into the perfusate (Byron et al., 1986; Niven and 
Byron, 1988).  In such a case, solute in perfusate will increase mono-exponentially toward an 
asymptotic value equal to the initial condition, A0. The fraction of the administered dose (D) 
transferred to the perfusate (Fp) for a solute described by Scheme IV.1, is given as a function of 
time, t: 
		ܨ୔ ൌ ܨ௔ ൈ ሺ1 െ eି௞౗୲ሻ                           eq. IV.1 
where Fa is the absorbable fraction (= A0/D) and ka is the apparent first-order rate constant for 
absorption. 
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 In the case of other non-metabolized drugs that are absorbed by apparent first-order kinetics, 
binding or sequestration to lung tissue can be modeled in accord with Scheme IV.2.  This Scheme 
differs from Scheme IV.1 because of the addition of a “bound drug” compartment (B) and the 
association and dissociation rate constants (k12 and k21). In Scheme IV.2, which is analogous to a 
two-compartment pharmacokinetic model, the drug in A and B should behave in a similar fashion 
to drug in plasma and drug in tissue, respectively, whereas drug in P should behave in the same 
way as cumulative elimination. Thus, the fraction in the perfusate, Fp, for Scheme IV.2 is given 
by a rearranged form of eq. 216 from Gibaldi and Perrier(Gibaldi and Perrier, 1975)  and the data 
for drug in perfusate should conform to 
ܨp ൌ ܨa ∗ ሺ1 െ ௞ೌିఉఈିఉ eିఈ୲ െ	
ఈି௞ೌ
ఈିఉ eିఉ୲ሻ                                                   eq. IV.2 
  where  ߙ ൌ ൫݇௔ ൅ ݇ଵଶ ൅ ݇ଶଵ ൅ ඥሺ݇௔ ൅ ݇ଵଶ ൅ ݇ଶଵሻଶ െ 4݇ଶଵ݇௔	൯/2    
   and     ߚ ൌ ൫݇௔ ൅ ݇ଵଶ ൅ ݇ଶଵ െ ඥሺ݇௔ ൅ ݇ଵଶ ൅ ݇ଶଵሻଶ െ 4݇ଶଵ݇௔	൯/ 2. 
 
 
U
D
A
ka 
P 
Scheme IV.1 Kinetic models describing solute (fluorescein) dosing and absorption from the 
airways of the IPRL in the absence of tissue binding or sequestration. Compartmental 
abbreviations show the administered dose (D), the untransferable (unabsorbable) amount of 
each dose (U), and the absorbable amount, A, (D=U+A), where P is the amount absorbed into 
the perfusate at time t. The apparent first-order rate constant for absorption from the airways is 
designated as ka. 
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In this current study, the dynamic dialysis techniques, first described by Meyer and 
Guttman and used subsequently by other groups to study solute-ligand binding (Bottari et al., 
1975; Hashimoto et al., 1984; Hiji et al., 1978; Meyer and Guttman, 1968; 1970; Pedersen et 
al., 1977; Sparrow et al., 1982), were first used to support the use of the IPRL binding and 
sequestration model described in Scheme IV.2. When dynamic dialysis under sink conditions 
is used to extract solutes from sliced IPRL tissue following initial airway dosing to that tissue, 
a model analogous to Scheme IV.2, Scheme IV.3 applies (Meyer and Guttman, 1968). In 
contrast to Scheme IV.2, Scheme IV.3 lacks an untransferable component, i.e. U = 0, because 
all of D that is administered to the airways becomes available for dialysis, so the amount 
released into the receiver solution, R, becomes equal to D as t tends to infinity. Furthermore, 
the binding or sequestration rate constants, k12' and k21', differ from those in Scheme IV.2 
because sliced tissue and drug release from the dialysis sac differ from the intact IPRL. The 
k21 
U
ka 
D 
A
P
B
k12 
Scheme IV.2 Kinetic models describing solute (tobramycin) dosing and absorption from the 
airways of the IPRL in the presence of tissue binding or sequestration. Compartmental 
abbreviations show the administered dose (D), the untransferable (unabsorbable) amount of 
each dose (U), and the absorbable amount, A, (D=U+A), whereas P and B are the amount of 
drug absorbed into the perfusate and the amount of drug bound to, or sequestration in, tissue at 
time t, respectively. The apparent first-order rate constant for absorption from the airways is 
designated as ka, whereas k12 and k21 are first-order association and dissociation rate constants 
for binding or sequestration. 
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first-order rate constant for solute release, ke, from a dialysis sac into R depends largely on the 
diffusive properties of the solute and the conditions of dialysis. However, the fraction of 
administered dose remaining in the sac (At /A0), at time t, should be a reflection of the solute’s 
tissue binding, and should theoretically conform to eq. 218 from Gibaldi and Perrier (Gibaldi 
and Perrier, 1975) , where 
                ܣ௧ ܣ଴ൗ ൌ 	
௞೐ିఉ
ఈିఉ eିఈ୲ ൅	
ఈି௞೐
ఈିఉ eିఉ୲                                                            eq.  IV.3 
     in which     ߙ ൌ ቀ݇ୣ ൅ ݇ଵଶ′ ൅ ݇ଶଵ′ ൅ ඥሺ݇ୣ ൅ ݇ଵଶ′ ൅ ݇ଶଵ′ሻଶ െ 4݇ଶଵ′	݇ୣ	ቁ/2    
     and            β ൌ ቀ݇ୣ ൅ ݇ଵଶ′ ൅ ݇ଶଵ′ െ ඥሺ݇௘ ൅ ݇ଵଶ′ ൅ ݇ଶଵ′ሻଶ െ 4݇ଶଵ′	݇ୣ	ቁ/2 
 
 
 
 
 
 
IV.b  MATERIALS AND METHODS 
 Experimental Design. Tobramycin, mannitol and fluorescein were administered in different 
aqueous solution formulations, by forced intratracheal instillation, to the airways of the 
ke 
D A
R
k12'
k21'
B
Scheme IV.3: Kinetic model describing solute dosing and dialysis from the IPRL in the 
presence of tissue binding or sequestration; the dialysis sac is shown diagrammatically as 
a dashed line. Compartmental abbreviations show the administered dose (D) and the 
dialyzable amount, A, (A=D), while R and B are the amount released into the receiver 
solution and the amount of drug bound to or sequestered in tissue at time t, respectively. 
The apparent first-order rate constant for dialysis is designated as ke, while k12' and k21' are 
the association and dissociation rate constants for binding/sequestration to the sliced 
tissue. 
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isolated perfused rat lung preparation (Figure IV.1) using a previously described method 
(Byron and Niven, 1988). Using this technique, studies were performed to explore the kinetics 
and mechanisms responsible for tobramycin’s pulmonary disposition. IPRL Absorption 
Studies were performed to elucidate the effects of concentration on airway-to-perfusate 
transfer (absorption). Prior to the analysis of data from those studies, IPRL Binding Studies 
were performed using dynamic dialysis (Meyer and Guttman, 1968). Those binding 
experiments employed identical surgical preparation, perfusion and airway dosing as those 
for IPRL Absorption Studies, after which the extent and rate of tobramycin and/or mannitol 
dialysis from lung tissue was determined. 
 
   
 
 
 
 
Animals. Specific pathogen-free, 300–400g, male Sprague-Dawley rats (Hilltop Lab 
Animals Inc., Scottsdale, PA) were used throughout. The animals were housed with access to 
water and food at 30-70% relative humidity (RH) and 18-26˚C, and a 12-hr light/dark cycle 
Figure IV.1 The IPRL preparation showing perfusate circulation. The lung was suspended 
horizontally in the artificial glass thorax (AGT) after cannulation of the pulmonary artery 
and trachea (Sakagami, 2006). 
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for ≥ 2 days before sacrifice. All procedures were approved by the Institutional Animal Care 
and Use Committee (IACUC) at Virginia Commonwealth University. 
 
  Chemicals and Materials. Tobramycin (≥98% free base) and bovine serum albumin, 
BSA, ≥98% (agarose gel electrophoresis) lyophilized powder (Sigma-Aldrich, St Louis, MO) 
were stored according to USP-NF 2007 (United States Pharmacopeia and National Formulary, 
2007)  . Krebs-Henseleit solution (KHS) containing 4% (w/v) BSA (K4) was freshly prepared 
and used as perfusate in the isolated perfused rat lung preparation. [3H]tobramycin and 
[3H]mannitol solutions (0.8 Ci/mmol, 1 mCi/mL; 10-30 Ci/mmol, 1 mCi/mL, respectively) 
were purchased from Moravek Biochemicals (Brea, CA) and PerkinElmer Life and Analytical 
Sciences (Waltham, MA), and sodium fluorescein (F-Na) was obtained from Arocos Organics 
(Geel, Belgium). Ecoscint XR scintillation cocktail (National Diagnostics, Atlanta, GA) was 
used for liquid scintillation counting. Other chemicals were purchased from Fisher Scientific 
(Pittsburgh, PA). Dialysis Tubing (Snakeskin®, 10K molecular weight cut-off, MWCO; 
Thermo Scientific, Rockford, IL) was washed with water and immersed in aqueous buffer 
solutions for >30mins prior to use.   
 
Dosing Solutions.  Aqueous radiolabeled tobramycin solutions were prepared in different 
concentrations (100, 20, 2, 0.2, 0.04 and 0.02 mg/mL) containing a nominal radiolabel content 
of 18 µCi/mL in 0.45% w/v NaCl and adjusted to pH 7.4 with H2SO4. Radiolabeled mannitol 
was prepared with different concentrations at 12 µCi/mL, while sodium fluorescein (unlabeled) 
solutions were prepared in pH 7.4 phosphate buffer and used at a concentration of 0.2 mg/mL. 
While the majority of the experiments involving tobramycin were performed with dosing 
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solutions containing 0.45% w/v NaCl (1/2NS), osmolality was varied in some investigations 
by using different concentrations of sodium chloride. 
 
IPRL Binding Studies. A dynamic dialysis method (Meyer and Guttman, 1968) was 
modified to investigate solute binding or sequestration to lung tissue. Tobramycin binding 
was investigated across doses (0.002, 0.004, 0.2 and 2 mg) by comparing its interaction with 
lung tissue to that of mannitol (a non-binding solute). In binding studies, the IPRL preparation 
was used and dosed in exactly the same way as described later for IPRL Absorption Studies. 
After dosing, the isolated lung preparation was taken out of the artificial glass thorax (AGT), 
sliced into 60-90 rectangular pieces (maximum linear dimension = 4mm) and transferred to a 
dialysis sac (dry length: 15 cm, washed and immersed in KHS solution prior to use) with 10 
mL of K4. To determine the intrinsic diffusive properties of tobramycin and mannitol in this 
system, solute dialysis was also studied in the absence of lung tissue and BSA, from sacs with 
identical total volumes of KHS.  Sacs were closed, with minimal headspace, by ligating with 
cotton thread, after which they were immersed at time zero in the perfusate reservoir 
containing 200 mL magnetically-stirred receiver solution (KHS or K4) maintained at 37˚C 
and pH 7.4.  The solute mass enclosed in the sac at time zero (A0) was determined by 
subtracting the solute lost during lung slicing (by assay of rinse solutions used in the procedure) 
from the administered dose, D (determined as described in the IPRL Absorption Studies). 
One mL samples were removed for assay from the receiver solution at 5, 10, and 20 minutes 
after which a 100 mL samples was withdrawn at each time point of 30, 60, 90, 120, 180 
minutes and hourly thereafter. An equal volume of solute-free receiver solution (37oC) was 
added to replace each sampling aliquot and restore the receiver volume to 200 mL. The 
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amount of solute remaining in the sac as a function of time (At) was calculated assuming mass 
balance.  
 
 IPRL Absorption Studies.  Use of the IPRL preparation (Figure IV.1) to study solute 
absorption was carefully controlled as described previously (Byron and Niven, 1988; Sun et 
al., 1999). Briefly, a rat lung was surgically removed and housed in an artificial glass thorax 
(AGT) maintained at 37˚C. Krebs-Henseleit solution (KHS) with 4% (w/v) BSA was used as 
perfusate (K4; 200 mL) and recirculated through the pulmonary circulation via the pulmonary 
artery at a constant flow rate of 15 mL/min.  A metal dosing cartridge containing 0.1 mL 
dosing solution was inserted into the trachea via a tracheal cannula. A metered dose inhaler 
(MDI, 25 μL drug-free CFC propellants per actuation) was connected to the dosing cartridge 
and actuated once. The dosing solution was propelled into the lung as a coarse spray, and the 
lung was inflated simultaneously to ~6 mL. The dosing cartridge was removed and the lung 
allowed to deflate (Byron and Niven, 1988). The administered dose (to the airways of the 
IPRL) was determined from the initial weight of the primed dosing cartridge, solution density 
and concentration after subtracting the mass remaining in the dosing cartridge after 
administration (determined by assay). The perfusate samples were taken from the well-mixed 
reservoir at time zero (blank sample, immediately prior to dosing) and subsequently at 1, 3, 5, 
10, 15, 20, 30, 40, 50, 60, 75, 90, 105 and 120 min following dosing. Solute concentrations 
were determined as described under “Assay Methods”. Sufficient IPRL studies were 
performed to yield no less than four fully viable preparations for each dosing solution, as 
evidenced by the absence of any signs of edema onset over 120 min (preparations that were 
“nonviable” at times < 120min were discarded). We have shown previously, and observe 
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consistently with this preparation, that “signs of edema onset” occur when the (blood-free) 
lungs change in outside color and texture from smooth white to a grey and/or patchy 
appearance; this appearance change is an early indicator of the preparation’s declining 
viability, shortly after which values for the wet lung/dry lung weight ratio, epithelial 
permeability to solutes and other effects change markedly (Byron et al., 1986; Niven et al., 
1990). At the end of each IPRL absorption study, the lung tissues were collected, homogenized 
and assayed for solute remaining in both the airways and the lung tissue. 
 
Assay Methods.  [3H]Tobramycin and [3H]mannitol concentrations were determined by 
scintillation counting relative to standards prepared freshly for each experiment (Liquid 
Scintillation Analyzer, Tri-Carb 2800-TR, PerkinElmer Life and Analytical Sciences) after 
first validating the radioactivity assay for tobramycin with high performance liquid 
chromatography–mass spectrometry (HPLC-MS) to ensure that chemical degradation and/or 
metabolism did not occur in lung tissue or perfusate over the duration of a typical experiment 
(see Appendix III and IV). In brief, perfusate samples containing radiolabeled solutes were 
used neat or diluted in K4. One milliliter aliquots were added to 5 mL scintillation cocktail 
(Ecoscint XR; National Diagnostics) in 7-mL polypropylene scintillation vials and well mixed. 
Total radioactivity was expressed as disintegrations per minute. Disintegrations per minute 
from accurately prepared [3H]tobramycin or [3H]mannitol standard solutions in K4 were 
measured independently for each assay series in order to calculate solute concentrations in 
unknown test solutions. Fluorescein concentrations in perfusate were assayed by 
spectrofluorophotometer (RF-5301 PC, Shimazu Corporation, Kyoto, Japan; λex and λem = 490 
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and 520 nm, respectively), as described earlier (Byron and Niven, 1988; Byron et al., 1986; 
Sakagami et al., 2002). 
 
Data analysis. Kinetic Analysis was performed according to the theory described above 
and Schemes IV.1-3. The data from IPRL binding studies using dynamic dialysis were 
expressed in accord with Scheme IV.3, as the fraction of the solute dose (At/A0) remaining in 
the sac as a function of time. The ke value for tobramycin was first determined by studying its 
dialysis kinetics in the absence of IPRL components (tissue and protein).  In this case, linear 
regression analysis of the first-order data for ln [At/A0] versus t was performed to determine 
its value (Meyer and Guttman, 1968). The binding rate constants, in the presence of lung tissue, 
k12' and k21', were then determined by fitting data for [At/A0] versus t to eq. IV.3 by least mean 
square non-linear regression analysis. The value for ke was fixed, whereas k12' and k21' were 
allowed to float. Goodness-of-fit was assessed using the calculated r2 and model selection 
criterion (MSC) by Scientist 3.0 (MicroMath Scientific Software, Salt Lake City, UT). Data 
from IPRL Absorption Studies were grouped in accord with the nominal dose initially added 
to the dosing cartridge. Each nominal dose resulted in a mean value for D (Scheme IV.1), due 
to solution retention in the cartridge. Fluorescein absorption into perfusate was expressed as 
the mean fraction of each administered dose reaching the perfusate, Fp, versus time. Best 
estimates for fluorescein’s mean absorbable fraction, Fa (=A0/D; Scheme IV.1) and its 
apparent first-order rate constant for absorption, ka, were obtained by fitting the unweighted 
data for Fp versus time to eq. IV.1 using Scientist 3.0. Because fluorescein that penetrates the 
airways proximal to the circulating perfusate is known to be completely absorbed, this 
provided a mean value for the solute’s eventually absorbable fraction, Fa that could be used 
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across solutes. Tobramycin data was analyzed according to Scheme IV.2, where best estimates 
for the rate constants describing binding and absorption (k12, k21, ka) at different nominal doses 
were determined by curve-fitting tobramycin Fp (fraction of administered dose in perfusate) 
versus time data to eq. IV.2.  
 
IV.c  RESULTS 
 
IPRL Binding Studies.  Tobramycin dialysis from the sac is shown as mean At /A0 
(fraction of administered dose remaining in the sac) versus time in Figure IV.2A. Biphasic 
(biexponential) profiles resulted from experiments in which drug release from sliced lung 
tissue occurred after airway dosing to the IPRL at five different dose levels; smaller doses 
showed greater values for tissue retention with time. In the absence of lung tissue, control 
experiments showed mono-exponential (apparent first-order) release of tobramycin from the 
dialysis sac under sink conditions (Meyer and Guttman, 1968). Following the data analysis, 
the mean dialysis rate constant, ke (Scheme IV.3), for tobramycin was found to be dose-
independent (0.0107±0.0021min-1; Figure IV.2A). Mannitol, a nonbinding solute, produced 
monoexponential and dose-independent At /A0 profiles in the presence and absence of IPRL 
tissue (Figure IV.2B). Tobramycin dialysis data from IPRL tissue (Figure. IV.2A) was fitted 
to eq. IV.3 to produce the best estimates of the rate constants in Scheme IV.3. These are shown 
in Table IV.1 for each dose; dashed curves in Figure IV.2A were produced by simulation 
using the rate constant values shown in the table. Tobramycin’s dissociation rate constant (k21') 
was effectively dose-independent, whereas k12' appeared saturable and decreased with 
ascending dose.  
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 Table IV.1: Best estimates (95% CI) of tissue binding/sequestration rate constants in Scheme 
IV.3 (eq. IV.3) from dynamic dialysis alongside the coefficient of determination, r2, and “model 
selection criterion” (MSC).  
The value of ke was fixed at 0.0107 min-1, its value in the absence of lung tissue. 
Dose 
mg 
k12' 
min-1 
k21' 
min-1 k12'/k21' r
2 MSC 
0.002 0.0174 (0.0160-0.0189) 0.0041 (0.0033-0.0048) 4.29 0.9999 5.74 
0.004 0.0112 (0.0099-0.0124) 0.0037 (0.0027-0.0046) 3.02 0.9998 5.70 
0.2 0.0094 (0.0087-0.0100) 0.0043 (0.0037-0.0050) 2.17 0.9999 7.03 
2 0.0070 (0.0060-0.0080) 0.0038 (0.0025-0.0051) 1.83 0.9997 5.89 
10 0.0052 (0.0031-0.0074) 0.0039 (0.0033-0.0045) 1.3. 0.9982 4.29 
 
Time (minutes)
0 60 120 180 240 300 360
A
t /
 A
0
0.1
0.3
0.5
0.7
0.9
0.0
0.2
0.4
0.6
0.8
1.0
Time (minutes)
0 60 120 180 240 300 360
A
t /
 A
0
0.1
0.3
0.5
0.7
0.9
0.0
0.2
0.4
0.6
0.8
1.0
BA
Figure IV.2. Mean fraction of solute remaining in the dialysis sac, At/A0, versus time. (A) 
Tobramycin at different nominal doses. Dashed lines show the best fits to eq. IV.3. Error 
bars are sample SDs (n≥3).  , 0.002 mg; , 0.004 mg; , 0.2 mg; , 2 mg; ,10 mg; , 
control (tobramycin 2 mg and 0.002 mg in absence of IPRL). (B) Mannitol at two nominal 
doses. , 0.02 mg; , 2 mg; , control, (0.02 mg of mannitol in absence of IPRL). 
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 IPRL Absorption Studies.   Fp versus time data for fluorescein (Figure IV.3) was fitted to eq. 
IV.1 to obtain best estimates of the absorbable fraction (Fa) and the first-order rate constant for 
absorption (ka) for this nonbinding solute; the values were 0.75 and 0.076 min-1, respectively 
(Table IV.2). Although mannitol absorption was too slow to reach an asymptote within the IPRL’s 
viable lifetime (Sun et al, 1999), its ka values shown in Table IV.2 were derived by fitting mannitol 
data to eq. IV.1 assuming that the absorbable fraction, Fa, was the same as that of fluorescein (Fa 
= 0.75). While that assumption may not be completely accurate, the approach was supported by 
the absence of a statistical difference between mannitol’s Fp (fraction of administered dose in 
perfusate) versus time profiles at different nominal doses (0.02 and 2 mg; t-test, p < 0.05; data not 
shown) and the agreement of ka values (Table IV.2) with reports in the literature for mannitol in 
the in situ rat lung where absorption half lives were derived by measuring solute disappearance 
from the lung (Brown and Schanker, 1983).  In contrast to fluorescein and mannitol, tobramycin’s 
absorption was clearly dose-dependent, the rate and extent of its pulmonary absorption increasing 
with the magnitude of the administered dose (Figure IV.3). At 120 minutes following tobramycin 
administration, the values for mean Fp (± SD; nominal dose) were 0.449 (± 0.024; 0.002 mg); 
0.505 (± 0.021; 0.02 mg); 0.587 (± 0.028; 0.2 mg) and 0.612 (±0.050; 2 mg). Tobramycin’s Fp 
versus time data showed good agreement with Scheme IV.2 and eq. IV.2, as indicated by the 
continuous curves shown in Figure IV.3. Best estimates of the rate constants used to generate these 
curves are reported in Table IV.2 alongside the values for the coefficient of determination, r2, and 
the model selection criterion (MSC). The rate constant for absorption appeared to be dose-
independent (range from 0.065 to 0.070 min-1) and close to that of fluorescein (0.076 min-1). The 
rate constant for dissociation from intact IPRL tissue (k21) was also relatively constant (0.018-
0.022 min-1), while that for association (k12) decreased from 0.164 to 0.072 min-1 with increasing 
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airway dose from 0.002 to 2 mg. As a result, the ratio of k12/ k21 decreased from 8.9 to 3.4 when 
the nominal dose was increased from 0.002 to 2 mg. 
 
 
 
 
 
 
 
 
Time (minutes)
0 30 60 90 120
M
ea
n 
Fp
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
Figure IV.3. Mean Fp = mean (±SD) fraction of administered dose (D) transferred to the 
perfusate versus time for fluorescein (nominal dose: 0.02 mg; open symbols) and 
tobramycin (closed symbols) in the IPRL. Nominal doses were 0.002 (; n=6); 0.02mg (; 
n=5); 0.2mg (; n=5) and 2mg (; n=4). Solid curves are the best fits for all profiles to eq. 
IV.1 (fluorescein) and eq. IV.2 (tobramycin) based on Schemes IV.1 and 2, respectively. Fa, 
the absorbable fraction of the administered dose, was fixed at 0.75, whereas ka, k12, and k21 
were allowed to float to produce the best estimates shown in Table IV.2. 
56 
 
 
 
 
IV.d  Discussion 
 
 Binding of tobramycin and other aminoglycosides to various tissues has been used to 
explain the formation of deep compartments in pharmacokinetic studies  ” (Mingeot-Leclercq 
and Tulkens, 1999; Nagai and Takano, 2004; Stepanyan et al., 2011), some epithelial cells of 
which (e.g. kidney proximal tubule and inner ear hair cells) are associated with nephro- and 
ototoxicity (Hiel et al., 1993; Just and Habermann, 1977; Nagai and Takano, 2004; Todd and 
Hottendorf, 1995). It is noteworthy, and probably because of the physiologic existence of 
 Dose 
mg 
ka 
min-1 
k12 
min-1 
k21 
min-1 
k12/k21 r2 MSC 
Tobramycin 
0.002 0.0651  
(0.0150-0.0852) 
0.1639  
(0.0970-0.2308) 
0.0184  
(0.0161-0.0207) 
8.91 0.9998 6.04 
0.02 0.066  
(0.0572-0.0748) 
0.1307 
(0.1226-0.1388) 
0.0205 
(0.0184-0.0225) 
6.38 0.9998 6.06 
0.2 0.0695  
(0.0610-0.0781) 
0.0905  
(0.0714-0.1097) 
0.0223  
(0.0199-0.0246) 
4.06 0.9999 6.89 
2 0.07 
(0.0626-0.0774) 
0.0721  
(0.0575-0.0867) 
0.0214  
(0.0189-0.0239) 
3.37 0.9999 6.82 
Mannitol 
0.02 0.0184 
(0.0154-0.0213) 
   0.9896 2.25 
2 0.0198 
(0.0180-0.0216) 
   0.995 3.45 
Fluorescein 0.02 0.0761 
(0.0694-0.0828) 
   0.9988 4.8 
Table IV.2. Estimated parameters (95% CI) and goodness-of-fit for different solutes in 
accord with Scheme IV.1 (fluorescein and mannitol) and Scheme IV.2 (tobramycin) in the 
IPRL Absorption Studies with Fa = 0.75. 
  
Blank cells for k12 and k21 indicate data consistent with Scheme IV.1. 
57 
 
these drugs as polycations, transfer into cells is slow and intracellular sequestration can be 
persistent. In the hope of elucidating the drug’s binding to and/or intracellular sequestration 
by lung tissue, dynamic dialysis was performed both in the presence and absence of tissue, 
and from the sliced IPRL, after dosing the airways using the same technique as that used for 
IPRL absorption studies. The open circles in Figure IV.2A show the apparent first-order, dose-
independent dialysis of tobramycin in the absence of lung tissue in which there was no 
evidence of drug binding. The comparator data shown in Figure IV.2B, for the nonbinding 
solute mannitol, was monoexponential and dose-independent (r2 >0.98) both in the presence 
and absence of tissue, indicating only that the presence of sliced lung tissue slightly reduced 
the value of ke for diffusive release from the sac (Scheme IV.3; ke for mannitol = 0.025 and 
0.019 min-1 in the absence and presence of sliced IPRL tissue, respectively) by hindering 
diffusion. Most notably, the tobramycin data for At /A0 (fraction of administered dose 
remaining in the sac) versus time at different doses in the presence of lung tissue were 
described well by eq. IV.3 and Scheme IV.3 (r2>0.998) showing clear evidence of dose-
dependent lung tissue binding or sequestration, as summarized by the decreasing values for 
the forward binding rate constant, k12' and the ratio k12'/k21' as doses were increased (Scheme 
IV.3, Table IV.1). While the model described in Scheme IV.3 assumes that tissue binding is 
zero at t=0 (and in practice, some binding must have occurred during the short period used for 
tissue slicing and dialysis set-up), these values for k12' and k21' implied that tissue binding 
occurred relatively slowly after airway administration and that all three rate constants in 
Scheme IV.3 had a similar order of magnitude. Efforts to determine whether significant  
binding/sequestration was due to tissue or the constituents of the IPRL airway lining fluid 
implied that lung tissues themselves were largely responsible for antibiotic sequestration. 
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Bronchoalveolar lavage samples; diluted with KHS containing low tobramycin concentrations 
(consistent with doses of approximately 0.002 mg) showed no difference in drug dialysis 
kinetics from the IPRL tissue-free control data for At/A0 in Figure IV.2A.  
 
This “slow-on” and “slow-off” binding behavior seen during dynamic dialysis supported 
the kinetic analysis of Fp versus time data in IPRL absorption studies. When the ex vivo IPRL 
was used, the values of the aminoglycoside’s binding constants in Scheme IV.2 (Table IV.2) 
were quantitatively different to those from the dialysis experiments (association and 
dissociation occurred faster under conditions involving absorption into perfusate), although 
the overall trend in the rate constant values was the same as that seen during dialysis. Neither 
fluorescein nor mannitol showed dose-dependent binding behavior and both showed 
monoexponential absorption properties (ka and Fa values) consistent with reports in the 
literature (Brown and Schanker, 1983; Byron and Niven, 1988). Tobramycin, however, 
showed decreasing rates of fractional absorption (transfer from airways to perfusate) as a 
function of decreasing dose and increasing binding/sequestration. Notably, dosing solution 
osmolality appeared to have no effect on Fp versus time data. For example, Fp at 120 min for 
a tobramycin dose at 0.2 mg in 0.9% w/v NaCl showed no statistical difference to that from 
0.2 mg in 0.45% w/v NaCl (t test, P < 0.05). However, the data for Fp versus time at different 
doses were described well by eq. IV.2 and Scheme IV.2 (r2>0.998) with clear evidence of 
dose-dependent and possibly saturable lung tissue binding summarized by the decreasing 
values for the forward binding rate constant, k12 and the ratio k12/k21 as doses were increased 
(Table IV.2).  The significant difference between the retention of this solute in lung tissue was 
related to tobramycin’s slow binding or sequestration following its administration. Values for 
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k21 appeared unrelated to dose, but values of k12 decreased as the dose was increased, but 
without evidence of capacity limitation. While the exposure of different tissue sites was 
clearly possible for absorption and dialysis experiments (IPRL was sliced immediately 
following dosing), the trend in the data for the lung tissue binding or sequestration constant, 
k12 (increases with decreasing dose) and k21 (effectively dose-independent), was consistent 
with the rate constant data for the sliced IPRL. 
 
To the best of our knowledge, this is the first work to investigate tobramycin binding to 
and/or sequestration by lung tissue and explore its effects on the drug’s pulmonary disposition 
following airway administration. Dynamic dialysis, initially used for protein binding studies, 
was successfully employed to study tissue binding and sequestration, and the results were 
consistent with those from the realistic ex vivo IPRL model. Based on the results, it was 
possible to calculate the apparent elimination half-life from the IPRL (equal to 0.693/β; eq. 
IV.2) as 2.3, 1.8, 1.3 and 1.2 hours for nominal doses of 0.002, 0.02, 0.2 and 2 mg, respectively. 
Notably, if binding did not occur, absorption into the perfusate (and thus, elimination from 
the IPRL) should occur with a half-life of a ~10 minutes (0.693/ka; Table IV.2), similar to that 
for fluorescein anions (Niven and Byron, 1988; Table IV.2). The 1.8-hour half-life at a 
nominal dose of 0.02 mg is consistent with the in vivo lung elimination half-life of 2.1 hours 
reported by Valcke and Pauwels (1991) in rat alveolar lining fluid following aerosol 
administration of a similar dose .  
 
In clinical treatment of humans, tobramycin inhalation solution (TOBI®; Novartis, Basel, 
Switzerland), the commercial nebulizer formulation used for cystic fibrosis patients, is 
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prescribed as an intermittent (28 days on/28 days off) treatment with 300 mg/5 mL nebulized 
and inhaled twice daily regardless of age (≥6 yrs) or body weight. Since the percentage of 
each nebulizer dose reaching the lung via the recommended PARI LC PLUS nebulizer has 
been reported to be ~15% (Lenney et al., 2011), a lung dose of ~45 mg could be expected in 
a 70-kg human. Based on weight scaling, this corresponds approximately to a nominal dose 
of approximately 0.2 mg to the airways of the rat lungs used in the IPRL studies described 
here, where the k12/k21 ratio was 4.06 (Table IV.2). Although species differences may well 
exist, similar cell constituents and concordance with alveolar surface area, lung volume, 
capillary volume and body weight have been reported across many species, including rats and 
humans (Crapo et al., 1983; Cryan et al., 2007; Plopper, 1983). Therefore, in conclusion, these 
studies in rat lung appear to support the existence of tobramycin retention in lung tissue 
following airway administration at doses likely to produce airway concentrations seen in 
humans. As a result of this slow-on and slow-off tissue binding or sequestration, the 
antibiotic’s longevity in the lung is extended. It is possible that this may account, at least in 
part, for the apparent success of tobramycin inhalation therapy seen in clinical practice. 
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Chapter V 
THE EFFECTS OF OSMOLALITY, pH AND TOBRAMYCIN CONCENTRATION OF 
DOSING SOLUTIONS ON AIRWAY EPITHELIAL INTEGRITY IN THE RAT LUNG 
FOLLOWING AIRWAY ADMINISTRATION  
 
 
 
V.a  INTRODUCTION 
 
Pharmaceutical formulators often aim to make solutions for inhalation isotonic with blood and 
neutral with respect to pH. In practice, they frequently compromise these “targets”, but need to 
observe certain limits for osmolality and pH deviations to avoid issues associated with airway 
irritation and potential pulmonary epithelial damage (Weber et al., 1997). Administration of non-
isotonic and non-physiologic pH solutions to the airways of sensitive individuals has been reported 
to cause cough, bronchoconstriction, airway hyperactivity, or bronchospasm (Eschenbacher et al., 
1984; Godden et al., 1986) and the occurrence of such airway reactions has sometimes been 
associated with alterations in pulmonary epithelial integrity, evidenced by an increase of 
intercellular space and the opening of tight junctions (Ohashi et al., 1992); this can lead to increases 
in airway epithelial permeation to solutes that diffuse via paracellular pathways, such as mannitol 
and 99mTc-DTPA (technetium-99 m-labelled diethylene triamine pentaacetic acid) (Wan et al., 
2000; Wells et al., 1994).  
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Aminoglycosides and other polycations in certain concentration ranges have also been reported 
to affect the integrity of various epithelia, including the airways, as manifested by increases in 
epithelial permeation and damage caused by the cytotoxicity of these compounds in vivo and in 
vitro (Dong et al., 2011; Florea et al., 2006; Karasawa and Steyger, 2011; Nagai and Takano, 2004; 
Schipper et al., 2000; Seki et al., 2008). As to aminoglycosides specifically, this class of drugs in 
certain concentration ranges has been reported to affect the permeation of vestibular epithelia and 
proximal tubular epithelia, and also could cause cell apoptosis and necrosis due to high local 
concentrations seen in studies of drug-induced oto- and nephro-toxicity (Karasawa and Steyger, 
2011; Kim et al., 2005; Todd et al., 1994). 
 
As all these factors may also perturb tobramycin’s disposition following airway administration, 
the IPRL studies in this chapter were aimed to validate tobramycin’s disposition model in the IPRL 
described in Chapter IV, or at least to define the boundaries of its applicability; this by planning 
and executing a series of experiments designed to eliminate alternate perturbation possibilities that 
could interfere with the binding models described earlier.  
 
V.b  MATERIALS AND METHODS 
 
IPRL Absorption Studies were performed using materials and general methods identical to 
those described in detail in Chapter IV of this thesis. Only the dosing solutions that were used for 
administration to the airways differed with respect to their formulation. Two separate series of 
IPRL Absorption Studies were performed in which the effects of realistic, but minor, variations 
in (i) dosing solution osmolality and (ii) dosing solution pH were studied. In a separate 
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experimental arm (iii) the effects of tobramycin concentration on mannitol’s absorption were 
investigated. For each dosing solution, no less than four fully viable preparations were studied and, 
as before, the absorption results from each group (n≥4) were expressed as mean cumulative 
fraction of the administered dose absorbed into the perfusate, Fp, versus time. 
(i) [3H] tobramycin dosing solutions at 2 mg/mL were prepared in 0.225 % or 0.9 % w/v NaCl 
and adjusted to pH 7.4 with H2SO4. The osmolality of these tobramycin dosing solutions and their 
2 mg/mL tobramycin counterparts described in Chapter IV (in which the vehicle was 0.45% w/v 
NaCl) were determined using the freezing point depression method using an Advanced® Model 
3320 Micro-Osmometer (Advanced Instruments, Inc., Norwood, MA), to measure and report the 
apparent osmolality of these solutions. Tobramycin absorption data obtained from these dosing 
solutions in 0.225 % and 0.9 % w/v NaCl were compared to the control data shown in Chapter IV, 
in which the same dose of tobramycin was administered in 0.45% w/v NaCl at pH 7.4. 
(ii) To elucidate the effects of pH of the dosing solution on tobramycin absorption, [3H] 
tobramycin dosing solutions at 2 mg/mL were prepared in 0.45% w/v NaCl and adjusted to pH 4.6 
or 8.6 with H2SO4 when necessary (pH of 2 mg/mL solutions of the base was ≥ 8.6). The absorption 
of tobramycin from these solutions was determined and compared to the control data at the same 
nominal tobramycin lung dose and pH 7.4 reported in Chapter IV.  
(iii) The effects of tobramycin concentration on mannitol absorption were investigated by 
studying the absorption of  [3H] mannitol from dosing solutions containing 0.2 mg/mL mannitol 
in 0.45% w/v NaCl and pH 7.4 to which  tobramycin (non-labeled) was added at 2, 20 and 60 
mg/mL. Mannitol’s absorption after its co-administration with these different tobramycin doses 
was investigated and compared to that of mannitol in the absence of tobramycin . 
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Statistical analysis  A repeated measures analysis of variance (ANOVA) was used to model 
mean tobramycin absorption as a function of time separately for each dosing solution (e.g. with 
different values of osmolality and pH),  and compare the drug’s absorption within different dosing 
solutions for each evaluation as described in Methods. The model included fixed effects for time, 
dosing solution, interaction between dosing solution and time, and a random effect by subject or 
IPRL preparation. A Bonferroni multiple comparison procedure was used to adjust the overall 
significance level with α = 0.05.  
 
V.c  RESULTS AND DISCUSSION 
 
As described in the conclusion to Chapter IV, and because the percentage of nebulizer doses 
likely to reach the lung from the recommended PARI LC PLUS nebulizer is ~15% (Lenney et al., 
2011), a lung dose of ~45 mg would be expected in a 70-kg human inhaling TOBI, in accord with 
the manufacturer’s instructions, twice daily (TOBI is formulated at 60mg/mL in 1/4 Normal Saline 
(NS) or 0.225% w/v NaCl). The experiments in this thesis using the IPRL were designed to bracket 
the likely doses (and thereby airway surface concentrations) seen in humans, based on weight 
scaling, where a lung dose of 45mg corresponds approximately to 0.2 mg in the airways of the rat 
lungs used here. The justification for this approach was based on the literature in which similar 
cell constituents and concordance with alveolar surface area, lung volume, capillary volume and 
body weight have been reported across species, including rats and humans (Crapo et al., 1983; 
Cryan et al., 2007; Plopper, 1983). The experiments described in this chapter in which the effects 
of pH and osmolality were evaluated were focused therefore on a single nominal dose of 0.2 mg 
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delivered to the airways by intratracheal administration of 2 mg/mL tobramycin in a 0.1 mL coarse 
spray of solution in different vehicles. 
 
Effects of dosing solution osmolality on tobramycin absorption 
Table V.1 shows the experimentally determined osmolality values of tobramycin solutions 
prepared in 0.225, 0.45 or 0.9 %w/v NaCl. The absorption data for tobramycin at a nominal 0.2 
mg dose are shown, expressed as Fp as a function of time, from either highly hypotonic (80 
mOsmol/kg) through isotonic (298 mOsmol/kg) dosing solutions in Figure V.1.  
 
Table V.1 Osmolality of tobramycin solutions at different concentrations at pH 7.4 (±0.2) prepared 
in 0.9% (normal saline, NS), 0.45% (1/2 NS) or 0.225% w/v NaCl (1/4 NS) solution. 
 
Tobramycin concentration 
Vehicle mOsmol/kg mg/mL mmol/L 
0 0 1/2NS 150 
0.02 0.04 1/2NS 151 
0.2 0.4 1/2NS 150 
2 4.3 1/2NS 157 
2 4.3 NS 298 
2 4.3 1/4 NS 80 
20 42.8 1/2NS 195 
60 128.5 1/2NS 257 
100 214.1 1/2NS 330 
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Figure V.1 Mean cumulative fraction of administered dose versus time following administration 
of tobramycin in vehicles with different osmolality. Tobramycin dosing solutions used in these 
experiments contained 2 mg/mL tobramycin at pH 7.4 in 0.9 % (normal saline, NS), 0.45% (1/2 
NS), and 0.225% w/v NaCl (1/4 NS). Error bars are sample standard deviation (n=4 or 5).   
 
The osmolality of the dosing solutions that were studied appear to be representative of the range 
used in clinical practice. The absorption data show clearly that no statistical difference in 
absorption kinetics was detectable in the IPRL throughout the 2 h period of an IPRL experiment 
(p value > 0.0035) due to changing osmolality. Accordingly, the results imply that these changes 
in osmolality do not affect the modeling and interpretation of the drug’s disposition that are 
discussed in detail in Chapter IV. Furthermore, the results also indicate that for even these 
significant volumetric additions of solution to the epithelial surfaces of the lung (0.1 mL in a 300 
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g rat lung) failed to disturb the epithelial barrier sufficiently to change the absorption of the 
aminoglycoside. 
 
The values for osmolality that were measured are worthy of some further explanation however. 
The theoretical osmolality of 0.9%w/v NaCl (Normal saline or NS) is close to 300 mOsmol/kg 
(Sinko, 2006). The value seen in Table V.1 for the 2mg/mL tobramycin solution in NS is consistent 
with this value and shows the minimal contribution of the aminoglycoside to the overall osmolality 
at the concentrations used for the absorption studies (in which the contribution of tobramycin (≤2 
mg/mL or 4.3 mmol/L) was small). It is not until tobramycin concentrations reached and exceeded 
20mg/mL in 0.45% w/v NaCl, that a significant increase of osmolality was seen due to the drug 
itself; drug contributions of 45, 107, and 180 mOsmol/kg were calculated for concentrations at 20, 
60 and 100 mg/mL, respectively, by subtracting the osmolality contributed by the vehicle (150 for 
0.45% w/v NaCl) from the total osmolality of these solutions shown in Table V.1.  
 
Theoretically, at pH 7.4, tobramycin is expected to have around 2.5-3 positive charges based 
on the reported pKas for its amino groups and according to acid-base equilibrium theory (Szilagyi 
et al., 1993). If the number of charges per tobramycin molecule at pH 7.4 is equal to 2.5, there 
should also be an increase in osmolality due to the addition of sulfate ion concentration needed to 
bring about the pH adjustment to a value of 7.4. Theoretically therefore, ignoring the contributions 
of NaCl and assuming complete dissociation of tobramycin and sulfate ions in solution, the 
osmolality of part-neutralized tobramycin at 20, 60, and 100 mg/mL, should be close to 95, 289 
and 482 Osmol/kg, respectively, assuming that the density of these solutions was not significantly 
changed from that of water. The measured smaller osmolalities shown in Table V.1, due to the 
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tobramycin and sulfuric acid in the higher concentration pH 7.4 solutions, imply significant non-
ideality, perhaps due to ionic interactions, in the solutions containing 20, 60 and 100mg/mL (the 
theoretical osmolality of a 100mg/mL tobramycin solution in ½ NS at pH 7.4 is expected to be ~ 
632 mOsm/kg in the event of complete ionic dissociation). Notably however, these non-ideal  
results shown in Table V.1 for high concentration tobramycin solutions are consistent with the 
reported osmolalities for Tobramycin Solution for Inhalation (60mg/mL) in the monograph in 
United States Pharmacopoeia (USP), where the drug solution in ¼ NS should lie in the range 150-
200 mOsm/kg (USP29-NF24: http://www.pharmacopeia.cn/v29240/usp29nf24s0_m83766.html) 
and the experimentally determined osmolality values for tobramycin solutions at 40 and 80 mg/mL 
in sterile water, ½ NS or NS at neutral pH according to Law (Law, 2001).   
 
These large differences in osmolality that are seen between the experimental measurements and 
the theoretical calculations for tobramycin imply the existence of strong interionic interactions in 
solution. In an attempt to quantitatively assess this phenomenon, the practical osmotic coefficient 
of tobramycin, g, as a measurement of the drug’s dissociation, was estimated to be 0.47, 0.37 and 
0.37 for tobramycin concentration at 20, 60, and 100 mg/mL at pH 7.4, respectively, using the 
equation eq. V.1 (Sinko, 2006): 
݃ ൌ 	 	௠ை௦௠௢௟ೌ೛೛ೌೝ೐೙೟௩∗௠                                            eq. V.1 
where ܱ݉ݏ݉݋݈௔௣௣௔௥௘௡௧ refers to the contribution of osmolality by tobramycin as an electrolyte; 
v is the number of ions into which an electrolyte dissociates (a value of 2.25 for tobramycin sulfate 
was used, corresponding to 2.5 charges associated with tobramycin molecules in pH 7.4); m refers 
to the electrolyte molality and is assumed to be equal to the value of molarity, assuming the density 
of these solutions was not effectively changed from that of water.  
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Values of g ≤ 0.5 imply that tobramycin sulfate behaves as less than half of the total ions into 
which tobramycin sulfate theoretically dissociates in solution. Although it is difficult to understand 
this atypical electrolyte behavior and the mechanisms responsible for it, this uncommon colligative 
characteristic of tobramycin clearly shows the uniqueness of this compound as a polyvalent 
electrolyte.   
 
In the literature, it has been suggested that a solution for inhalation should have an osmolality 
between 150 and 550 mOsm/kg (Weber et al., 1997).  Others have reported that administration of 
non-isotonic solutions to the lungs via inhalation in the clinic are acceptable, even though such 
administrations may produce bronchial reactions manifested by cough, bronchoconstriction, 
airway hyperreactivity, or bronchospasm in some individuals (Eschenbacher et al., 1984; Weber 
et al., 1997). The effect of hypotonic solutions on the airway permeability of 99mTc-DTPA was 
evaluated by Wells et al. (Wells et al., 1994) who were able to show that enhanced airway 
permeation could be detected across isolated sheep trachea when the tracheal lumen was filled 
with hyposmolar fluid (128 mOsmol/kg).  Based on the results shown in Figure V.1, Wells’ 
findings do not appear to be relevant to the absorption of tobramycin from the airways of the rat 
lung. 
 
Effects of dosing solution pH on tobramycin absorption  
Mean cumulative fraction of administered dose absorbed into the perfusate, Fp, from dosing 
solutions of different pH are shown as function of time in Figure V.2.  Tobramycin dosing solutions 
were prepared at the same drug concentration, 2 mg/mL, but adjusted to three different pH values 
with the addition of sulfuric acid: values of pH = 4.6, 7.4 and 8.6, believed to be representative of 
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the range used in clinical practice. Statistically, administration of tobramycin under these 
conditions showed no alteration in the drug’s absorption kinetics when compared to the control (p 
value > 0.0035). It was noteworthy that administration of these basic or acidic dosing solutions to 
the IPRL airways appeared to have no effect on the isolated rat lung’s viability (no edema was 
observed during the typical 2 hours’ experiment period), and thus, it was probable that these pH 
values and the addition of solutions as coarse sprays failed to disrupt the epithelial integrity of the 
airways of the IPRL. Because the pH values that were chosen should affect the degree of ionization 
of the aminoglycoside, the results also implied that the modified ionization status of the amino 
groups in each tobramycin dosing solution had no effect on the drug’s absorption, binding or 
sequestration at this (realistic) dose and airway surface concentration. This could of course, simply 
be an indication that the buffering power of the organ and its circulating perfusate simply 
overwhelms the addition of a pH-modified solution bolus containing 2mg/mL tobramycin. 
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Figure V.2 Mean cumulative fraction of administered dose versus time, Fp, for tobramycin dosed 
at 0.2mg using 0.1mL of 2mg/mL solutions in 0.45% w/v NaCl at either pH 8.6, 7.4 or 4.6. Error 
bars are sample standard deviations (n=4 or 5).   
 
Effect of tobramycin concentration on mannitol absorption 
The absorption of the hydrophilic monosaccharide mannitol and/or its permeation rate through 
epithelial membranes is believed to be a measure of simple diffusion through hydrophilic “pores” 
or passive paracellular transport. In short, the solute is believed to be a marker for the integrity of 
tight junctions and the “leakiness” of epithelial monolayers such as those seen in the airways of 
the lung (Wan et al., 2000). Mannitol absorption data, therefore, should be usable as a surrogate 
measure of epithelial integrity in a preparation such as the IPRL; factors that accelerate its 
absorption, perhaps alter the barrier separating (in the IPRL) the airways from the perfusate. The 
results of IPRL absorption studies following airway administration of mannitol alone or its co-
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administration with unlabeled tobramycin in different concentrations, are shown in Figure V.3.  
The nominal lung dose of mannitol in all these IPRL studies was held constant at 0.02 mg/rat lung 
(0.2 mg/mL in a fixed solution volume of 0.1 mL). Quite clearly, co-administration 0.2 mg 
tobramycin with mannitol, failed to bring about alterations in mannitol absorption profiles (mean 
Fp versus time) when these were compared to the tobramycin-free control data (p value > 0.0035; 
Figure V.3). At the high dose extremes however, where tobramycin concentrations were 60 mg/mL 
or greater (nominal doses of 6mg or more), the disruptive effect of tobramycin on airway epithelial 
integrity could be seen clearly as a major accelerant for mannitol absorption in the IPRL (p value 
< 0.0035; Figure V.3). Notably, also at this dose, among a total of 7 rat lungs that were used for 
this experimental condition, only 4/7 showed a lack of edema over the 120 minute study; three rat 
lungs became edematous within one hour of dosing. This decrease in viability appeared to be due 
to the presence of high tobramycin concentration in the airway lumen, a conclusion that was 
supported by an attempt to investigate tobramycin’s absorption at a dose of 10 mg where edema 
was observed in all IPRL preparations within one hour of dosing.  These observations implied that 
the values for Fp versus time at the 6 mg dose were actually an underestimate of the true values, 
due to the obligatory discard of non-viable preparations.  
 
The tobramycin dose effect on mannitol absorption can also be seen, both in Figure V.3 and 
Table V.2, where values for Fp were compared to the tobramycin-free control at identical sample 
times and show that the effect begins to be manifested even at doses as low as 2 mg (0.1 mL, 
tobramycin concentration = 20 mg/mL), when both mannitol and tobramycin were administered 
in the same solution (p value < 0.0035). Although there was no observation this co-administration 
affected the isolated rat lungs’ viability as seen from a higher tobramycin dose of 2 mg, it is 
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possible that this dose level of tobramycin in the dosing solution could cause a certain degree of 
membrane disruption such as the cleavage of tight junctions and accelerated mannitol’s absorption.  
 
 
 
Figure V.3 Mean cumulative fraction of administered mannitol dose versus time. The closed 
circles refers to the mean Fp data from the administration of 0.02 mg mannitol alone, while the 
open symbols refer to the data from the co-administration of 0.02 mg mannitol with tobramycin at 
different doses. * indicates that the mean values of Fp were calculated from 4 out of 7 rat lungs, 
by discarding the results from the isolated rat lungs in which edema occurred during the 2 hr’s 
experiment period. 
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Table V.2 The increase in mean Fp for mannitol with time seen due to co-administration with 2 
or 6 mg tobramycin to the airways of the IPRL.  
 
Time (min) 
Δ Fp  
(Fp,coadministration- Fp,control)# 
2 mg 6 mg 
1 -0.007 0.028 
3 0.023* 0.125* 
5 0.061* 0.176* 
10 0.094* 0.245* 
15 0.118* 0.260* 
20 0.107* 0.242* 
30 0.119* 0.241* 
40 0.115* 0.221* 
50 0.115* 0.203* 
60 0.119* 0.183* 
75 0.093* 0.144* 
90 0.103* 0.139* 
105 0.058 0.082 
120 0.040 0.059 
 # control data for Fp was taken from the results of administration of mannitol alone at a lung 
dose of 0.02 mg. Statistical significance is shown as * (p value <0.0035). 
 
 
V.d  CONCLUSIONS 
 
Osmolality and pH variations in airway dosing solutions in the range 80 through 298 
mOsmol/kg and 4.6 to 8.6, respectively, failed to alter the rate or extent of tobramycin transfer to 
perfusate following airway administration to the IPRL in doses designed to produce airway 
concentrations typical of those used clinically. These experiments, that were referenced in the text 
of Chapter IV, are thought to be useful adjuncts to the data showing that aminoglycoside 
disposition following inhalation at clinically relevant doses is unlikely to be influenced 
significantly by small changes in formulation variables such as NaCl content and pH; there was 
no evidence that these changes affected the epithelial integrity of the IPRL. Tobramycin itself 
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however, was implicated as an agent capable of epithelial damage, when its effects were studied 
by co-administration with mannitol. To our knowledge, this is the first report of the effect of 
aminoglycosides on airway epithelial integrity. Based on the results however, drug induced 
epithelial changes are expected to be minimal at lung doses seen for the clinical treatment of 
humans.  
 
Tobramycin’s membrane damaging effects were clearly dose and concentration dependent 
however, and may begin to be seen at IPRL doses as low as 2 mg. While these experiments differed 
from those described in Chapter IV and involved mannitol administration in the same solution as 
the aminoglycoside, the slight elevation in the reported values for tobramycin’s ka with dose (Table 
IV.2) may have been due in part to the drug’s membrane toxicity. It is impossible to say whether 
this latter observation has any clinical significance, especially given the fact that the drug is mostly 
used to treat individuals with CF who have abnormal airway epithelia in the first place and the 
treatment of their infections is a clinical imperative. Overall, these findings appear to eliminate the 
possibilities that significant airway perturbations other than tissue binding and sequestration are 
responsible for the drug’s pulmonary pharmacokinetics, and that it is those phenomena that bring 
about the drug’s prolonged presence in the lung following airway administration. 
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Chapter VI 
SUMMARY AND CONCLUSIONS 
 
 
 
 
Nebulized tobramycin therapy has improved the health and well-being of many cystic fibrosis 
(CF) patients in spite of its pulmonary disposition being poorly understood. In this dissertation, a 
meta-analysis of the pharmacokinetic (PK) data in humans is described as a precursor to systematic 
series of experimental investigations using the isolated perfused rat lung preparation (IPRL). In an 
attempt to elucidate both the kinetics and extent of pulmonary absorption in humans, the 
bioavailability of inhaled tobramycin in healthy and CF adults was re-evaluated in Chapter III 
using both non-compartmental and compartmental approaches partnered with the drug’s intrinsic 
PK parameters obtained from intravenous (IV) studies in the literature. This work revealed that in 
both CF and healthy adults, tobramycin absorption from the lung following inhalation was more 
complete than is commonly assumed based on the drug’s theoretical behavior as an 
aminoglycoside poly-cation at physiologic pH (Szilagyi et al., 1993). However, due to the large 
variance seen in published studies of tobramycin’s intrinsic PK after IV administration, and the 
fact that patients, in which the drug’s inhalation blood level versus time curves were reported, 
differed from those used to determine tobramycin’s intrinsic PK, the overall results from meta-
analysis did not inspire much confidence in the accuracy with which the drug’s pulmonary 
bioavailable fraction in humans could be determined.  Likewise, in Chapter III, the rate of the 
drug’s absorption from the lung following inhalation, measured using different modeling 
techniques was found to produce apparent half lives for pulmonary absorption that ranged from 
0.7 through 2.3 hours. Data analysis difficulties were also noted for modeling with some of data 
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to determine absorption rate constants (see legend, Figure III.1), all of which assumed irreversible 
absorption from the airways into the systemic circulation. It was only following a review of the 
sputum concentration data in patients who had experienced repetitive aerosol dosing, that the 
existence of drug binding or sequestration in the lung became a possibility (see Table III.4) 
 
To enhance the understanding of the inhaled drug’s disposition kinetics and mechanisms, 
tobramycin’s absorption following airway administration was investigated systematically as a 
function of dose and local concentration, using a realistic ex vivo model, the IPRL, as described 
by Byron and Niven (1988). Tobramycin’s absorption, from airways to perfusate, expressed as 
cumulative fraction of the administered dose absorbed into the perfusate versus time, was seen to 
be bi-exponential and dose-dependent, unlike that seen for the marker solutes fluorescein and 
mannitol that both showed first-order and dose-independent kinetics (Chapter IV). HPLC-MS 
assay techniques were developed with a sufficiently small limit of quantitation (LOQ) to study the 
absorption of this chromophore-free aminoglycoside at some of the higher doses studied in the 
IPRL (Appendix I). Those assay techniques, when compared with the radiolabel assay (Appendix 
III) used for most studies reported in Chapter III produced statistically comparable absorption 
profiles (Appendix IV), showing that radiolabel degradation was not significant in the period of 
study. Furthermore, the dose-dependent disposition kinetics seen with tobramycin in the IPRL did 
not appear to be associated with metabolic degradation, since this class of drugs fails to undergo 
metabolism in the body and is excreted unchanged almost entirely by the kidney after IV 
administration (Israel et al., 1976; Schentag et al., 1978).  
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In this scenario, a kinetic model for tobramycin that incorporated lung tissue binding and/or 
sequestration alongside passive absorption was proposed and employed successfully to describe 
the aminoglycoside’s disposition in the IPRL following airway administration. Based on the rate 
constant data obtained from the kinetic model in the IPRL, tobramycin’s absorption occurred fast 
with first-order absorption rate constants (ka = 0.065-0.070 min-1) close to those seen with 
fluorescein (0.076 min-1), while a dose-, and concentration-dependent lung tissue binding 
mechanism, appeared able to prolong the drug’s presence in the rat lung. This dose-dependent 
tissue binding or sequestration appeared to potentially saturable, indicated by the fact in which 
forward binding rate constants (k12) decreased as doses (and administered concentrations) were 
increased, while backward rate constants (k21) appeared unrelated to dose (see Table IV.2).  
 
This kinetic model was validated using dynamic dialysis experiments involving elution studies 
from the whole sliced IPRL preparation. The dynamic dialysis techniques, advocated by Meyer 
and Guttman and used subsequently by other groups to study solute-ligand binding (Bottari et al., 
1975; Hashimoto et al., 1984; Hiji et al., 1978; Meyer and Guttman, 1968; 1970; Pedersen et al., 
1977; Sparrow et al., 1982), were modified and used with sliced IPRL tissues in this dissertation 
to study the lung tissue binding of tobramycin by directly mimicking the environment in which 
the drug was administered to the airways of the preparation. Those studies confirmed that tissue 
binding occurred relatively slowly after airway administration and that all three rate constants (for 
dialysis, association and dissociation) had a similar order of magnitude (see Scheme IV.3, Table 
IV.1). Although the binding sites remained unclear, lung tissues were shown to be clearly 
responsible for the antibiotic’s sequestration; this because the constituents of the IPRL airway 
lining fluid collected by bronchoalveolar lavage showed no significant binding to tobramycin in 
control dialysis studies. While such disposition models appeared to be consistent with observations 
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of prolonged sputum concentrations following repeated dosing in the clinic(Gibson et al., 2003; 
Govoni et al., 2013; Hubert et al., 2009), the human PK data for this drug were too variable to 
discern the magnitude of such effects (Chapetr III). Moreover, it is not known whether 
prolongation of tobramycin’s concentrations in the lung due to such binding enable better killing 
or whether the antimicrobial effects would be enhanced simply by maximizing the airway 
Cmax/MIC ratio for a short duration as discussed by MacArthur et al.(1984). 
 
It was unexpected that tobramycin could be absorbed from the airways of the IPRL faster than 
mannitol (ka = 0.018-0.019 min-1), a paracellular (hydrophilic) absorption marker with a much 
smaller molecular size (MW 182 Da) than tobramycin (MW 467.5 Da). While the mechanisms 
responsible for the drug’s apparent rapid absorption in the IPRL were not studied in this 
dissertation, it was noteworthy that tobramycin itself was found to affect airway epithelial integrity 
when co-administered at doses as large as 2 and 6 mg to the IPRL airways with mannitol. In this 
situation, mannitol’s absorption was accelerated when co-administered with tobramycin and the 
viability of the isolated lung preparation appeared to decrease when increasing tobramycin’s 
airway dose to the IPRL. The drug’s disruptive effects on airway epithelia however, were 
undetectable at a lung dose level of 0.2 mg in rats that was believed to produce similar airway 
concentrations to those seen in human patients using TOBI. Based on this reasoning, tobramycin 
induced epithelial changes are expected to be minimal at lung doses seen in the clinical treatment 
of humans by inhalation. To our knowledge, this is the first report of the effect of aminoglycosides 
on airway epithelial integrity even though this class of drugs in some concentrations have been 
reported to affect the permeation of vestibular and proximal tubular epithelia, and also cause cell 
apoptosis and necrosis due to high local concentrations (see studies of drug-induced oto- and 
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nephrotoxicity; Karasawa and Steyger, 2011; Kim et al., 2005; Todd et al., 1994). Whether this 
observation has any clinical significance, especially given the fact that the drug is mostly used to 
treat lung-infected individuals with CF, who have abnormal airway epithelia in the first place, is 
unknown. Nevertheless, these findings may add value to those dealing with formulation 
development and dosing strategy designs for other inhaled aminoglycosides. 
 
Overall, by eliminating the variability associated with systemic clearance, and performing a 
series of systematic investigations in an ex vivo lung preparation, this dissertation increased our 
knowledge of tobramycin disposition following airway administration. As a polycation at 
physiological pH (Szilagyi et al., 1993), the aminoglycoside showed a unique ability to bind or 
sequester in the lung that appeared to prolong the drug’s local presence and, thereby, extend its 
anti-infective effects following inhalation. The drug’s tissue binding properties may account, at 
least in part, for the apparent success of tobramycin inhalation therapy seen in clinical practice. 
The findings in this dissertation may also assist with development of future research in this 
important therapeutic area of antibiotic therapies for pulmonary administration, given that the 
models developed in Chapter IV enable kinetic interpretation of the clinical studies in humans in 
which repetitive dosing showed, albeit inconclusively, accumulation and prolonged antibiotic 
durations following topical delivery. Further exploration of the mechanisms responsible for 
aminoglycosides’ lung sequestration with other aminoglycosides, may enable future design and 
development of drugs for pulmonary administration with prolonged lung retention.  
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Appendix I 
HPLC MASS SPECTROMETRIC ANALYSIS OF TOBRAMYCIN IN PERFUSATE 
 
 
AI.a Introduction 
In this appendix, the development and validation of an HPLC-MS method suitable for 
tobramycin assay in perfusate in the IPRL is described. The method overcomes the adsorption 
problems of aminoglycosides on glass and other surfaces (Josephson et al., 1979) and employs 
solid phase extraction followed by reverse phase HPLC with trifluoroacetic acid (TFA) as an ion-
pairing agent. Mass detection using a single quadrupole mass spectrometer in positive detection 
mode with electrospray ionization (ESI) confers sensitivity and specificity.  
AI.b Methods and materials 
Chemicals and materials 
Tobramycin was purchased from Sigma-Aldrich (MO, USA), acetonitrile (CAN; HPLC-grade), 
methanol (HPLC-grade), buffer salts (KCl, KH2PO4, CaCl2, MgSO4, NaHCO3) and dextrose were 
supplied by Fisher Scientific (Pittsburgh, PA). Bovine serum albumin (BSA), trifluoroacetic acid 
(TFA) and heptafluorobutyric acid (HFBA) were purchased from Sigma-Aldrich (St. Louis, MO). 
Bond-ELUT-C18 cartridges (100mg, 1 mL) used for solid phase extraction (SPE) were obtained 
from Varian Inc. (Walnut Creek, CA). Pipette tips (200uL and 1000uL) and centrifuge tubes (2mL) 
were made of polypropylene (PPE) and purchased from Fisher Scientific. Small volume HPLC 
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vial inserts (250uL, PPE) were obtained from MicroSolv (Eatontown, NJ).  The perfusate (K4) is 
the modified Krebs-Henseleit solution(KHS) with 4% bovine serum albumin (BSA) (w/v) 
containing 4.7mM KCl, 143.3mM NaCl, 1.2mM MgSO4, 2.52mM CaCl2, 1.2mM KH2PO4, 5mM  
glucose, prepared as described in Chapter IV.  The perfusate pH was adjusted to 7.4 at room 
temperature; solutions were stored at 4°C and used within 48 hours. 
 
HPLC-MS method development 
 
 Chromatographic and mass spectrometric conditions. Alliance 2695 system (Waters, 
Milford, MA) was used for chromatographic separation by a Hypersil Gold C18 column 
(150×4.6mm, 3µm; Thermo Scientific, Waltham, MA). Isocratic elution at a flow rate of 0.3 
mL/min was used with the mobile phase consisted of acetonitrile (ACN): 0.1% v/v TFA water 
solution (volume fraction ratio, 30:70), where TFA functioned as an ion pairing agent to 
increase tobramycin’s retention on the column. Chromatographic performance (peak shape and 
symmetry) using mobile phase containing different TFA concentrations was assessed to 
determine the appropriate TFA concentration in the mobile phase for the analysis. The injection 
volume was hold at 10 μL. The mass spectrometry detector was a ZMD 4000 (Waters 
Corporation, Milford, MA) equipped with an electrospray interface in positive ionization mode. 
The parameters were set as: capillary voltage 3.78 kV; cone voltage 20 V; extractor 6 V; Rf 
Lens 0.1 V; source block temp 130 °C; desolvation temp 350 °C; nitrogen desolvation flow 600 
L/min. Tobramycin was determined by single ion monitoring (SIM) for the molecular ion 
[M+H]+ at m/z 468.61. Masslynx NT 3.5 (Waters) was used for the HPLC-MS system control 
and data processing.  
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Calibration standards and quality controls. The stock standard solution of tobramycin at 1 
mg/mL was prepared in water and further diluted with ACN –H2O (80:20) containing 0.4% TFA, 
to obtain the standard solutions at concentrations of 50, 20, 10, 5, 2, 1, and 0.5 µg/mL. These 
standard solutions were then diluted by 10 fold with blank perfusate to obtain perfusate calibration 
standards at concentrations of 5, 2, 1, 0.5, 0.2, 0.1, 0.05 µg/mL. Quality control samples in 
perfusate at the lowest limit of quantification (LLOQ) and low, medium and high concentration 
levels were prepared in triplicate in the same way as these calibration standards.  
Solid phase extraction and sample pretreatment. Tobramycin perfusate samples, calibration 
standards in perfusate and quality control samples were pretreated with 5% v/v HFBA water 
solution  in a volume ratio of 1:1 followed by centrifugation at 14,000 rpm for 10 minutes at 4 °C 
(Eppendorf, Centrifuge 5804R,  Hamburg, Germany) to enable protein precipitation and 
simultaneously, ion pairing. A volume of 1 mL supernatant solution was then taken from each 
sample and solid phase extraction was performed for sample clean-up with Bond-ELUT-C18 
cartridges (100mg, 1 mL) using the following procedure: 
Conditioning: 1 mL methanol and 1ml 5 mM HFBA water solution; 
Loading: 1 mL supernatant solution prepared above; 
Washing: 1 mL 5 mM HFBA water solution (×2); 
 Eluting: 1 mL ACN: H2O 90:10 (containing 1% v/v TFA). 
Eluent solutions collected in polypropylene (PPE) centrifuge tubes were evaporated to dryness 
at 40 °C under vacuum and reconstituted with the dilution solvent. These reconstituted solutions 
were transferred to 250 µL polypropylene (PPE) inserts and aliquots of 10 µL were injected onto 
the HPLC column.  
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The adsorption of tobramycin onto the surfaces of glass HPLC vials and polypropylene inserts 
were assessed using tobramycin standard solutions prepared in different dilution solvents. The 
dilution solvent was selected from H2O, ACN –H2O (80:20), ACN –H2O (30:70) containing 0.1% 
or 0.4% v/v TFA, and ACN –H2O(80:20) containing 0.1% or 0.4% v/v TFA, based on the results 
of screening experiments designed to assess peak shape, injection reproducibility and adsorption 
losses. The storage and transfer containers used in sample pretreatment were all made of 
polypropylene in order to avoid surface adsorption losses onto glass that have previously been 
reported with aminoglycosides (Josephson et al., 1979).  
 
Validation Procedures.  
Calibration. Perfusate calibration standards after solid phase extraction were analyzed by 
HPLC-MS. Tobramycin peak areas from the corresponding chromatograms versus nominal 
concentrations were fitted using a Masslynx regression method based on a best-fit procedure 
(Figure AI.3). Deviation of the calculated concentration of each calibrator from the nominal 
one, expressed as the percentage of the nominal concentration (% Dev), should be within ±15% 
except at the LLOQ level in which a deviation of ±20% was permitted.  
Accuracy, precision and extraction recovery. Accuracy was defined as the ratio, expressed 
as a percentage, of the experimentally determined concentration to the spiked drug 
concentration in each quality control sample. Precision was expressed by coefficient of 
variation, CV%, of the experimental determined concentrations of each quality control sample 
injected in 3 separate runs within a day  (= SD / Mean× 100%, where “Mean” is the mean of 
the experimentally determined concentrations from 3 separate runs and SD is the standard 
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deviation of the “Mean”). The efficiency and reproducibility of solid phase extraction was 
evaluated by extraction recovery rate, expressed as percentages, calculated by eq. AI.1: 
Extraction rate = ܣݎ݁ܽ௘௫௧௥௔௖௧௘ௗ ܣݎ݁ܽ௥௘௙௘௥௘௡௖௘൘ ൈ 100%                                   eq. AI.1 
     where ܣݎ݁ܽ௘௫௧௥௔௖௧௘ௗ  refers to the peak area obtained from each extracted quality control, 
ܣݎ݁ܽ௥௘௙௘௥௘௡௖௘  is the average peak area of tobramycin obtained from the standard solutions 
prepared in duplicate with the dilution solvent at the same nominal concentration as that in the 
quality control sample.   
 
Matrix effects.  
Matrix effects, defined as the impact of the perfusate components and endogenous metabolic 
byproducts derived from the dying IPRL tissue during recirculation through the rat lung 
vasculature on the assay’s accuracy, were assessed for “IPRL-free” blank perfusate and 4 batches 
of IPRL control perfuste, in which two batches of IPRL control perfusate (Batch 1 and 2) were 
obtained by circulating purfusate in the IPRL vasculature for 0.5 hour using two different rat lungs, 
and another two batches of control perfusate (Batch 3 and 4) were collected from the re-circulated 
perfusate using a third rat lung after 0.5 hour (Batch 3) and 2 hours (Batch 4). These four batches 
of IPRL control perfusate as well as “IPRL-free” blank perfusate sample were pretreated by solid 
phase extraction, and reconstituted with the dilution solvent. Matrix effects were evaluated using 
both a post-column infusion and a post-extraction addition method. In the post-column infusion 
method, tobramycin standard solution at 1000 ng/mL was infused into the MS detector by a syringe 
pump at a flow rate of 5 µL/min, while the mobile phase was also pumped to the MS detector at a 
flow rate of 0.3 mL/min operated by a Tee-valve device. Aliquots of 10 µL of reconstituted 
solutions of these perfusate extracts were injected onto the column when performing post-column 
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infusion. The chromatograms were collected based on single ion monitoring of m/z 468.61; a 
negative peak was expected to indicate signal suppression while a positive peak was expected 
show signal enhancement due to the components in the matrices. For the post-extraction 
addition method, only the batch of perfusate which was recirculated in IPRL for 2 hours and 
the “IPRL-free” blank perfusate, were used for this purpose.  These perfusate batches were 
sampled and extracted by solid phase extraction; after evaporating to dryness, a volume of 50 
μL standard solutions in dilution solvent at the concentrations of 50, 10, 1 μg/mL were added 
to the dried 2ml centrifuge tubes containing perfusate residues and diluted by 450 μL dilution 
solvent to produce tobramycin solutions at concentrations at 5000 (high), 1000 (medium), and 
100 (low) ng/ml (two replicates at each concentration for each batch of perfusate). The 
corresponding standard solutions at these concentrations were prepared similarly in duplicate 
but using 2 ml clean centrifuge tubes, as reference solutions. Matrix effects were evaluated by % 
deviation (% dev.) of mean peak area obtained from the injections of those solutions prepared 
with perfusate matrices ܣݎ݁ܽ௣௢௦௧ି௘௫௧௥௔௧ప௢௡തതതതതതതതതതതതതതതതതതതതതതത,	 from that in the reference solutions,	ܣݎ݁ܽ௥௘௙௘௥௘௡௖௘, 
calculated by: 
                          % dev. = ஺௥௘௔೛೚ೞ೟ష೐ೣ೟ೝೌ೟ഢ೚೙
തതതതതതതതതതതതതതതതതതതതതതതതതതതതି஺௥௘௔ೝ೐೑೐ೝ೐೙೎೐
஺௥௘௔ೝ೐೑೐ೝ೐೙೎೐ ൈ100%                     eq. AI.2 
 
Adsorption test on the IPRL apparatus.  
Since the IPRL apparatus included glassware, tobramycin adsorption onto the complete IPRL 
apparatus was assessed for perfusate samples at low concentration (100 ng/mL) in three replicates 
to evaluate the applicability of the IPRL standard apparatus for studies of tobramycin disposition. 
Briefly, 200 mL of blank perfusate was circulating in the IPRL apparatus at 37 ˚C simulating the 
real experimental condition except the absence of an isolated rat lung.  An aliquot of 0.1 mL 
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tobramycin solution in water at 200 µg/mL was added the perfusate, and sampling of perfusate 
from the IPRL system was begun at 5 minutes after adding the tobramycin solution and followed 
at 30, 60, 90 and 120 minutes. The experiment was repeated three times and the profiles of 
tobramycin concentration versus time were plotted and the adsorption of tobramycin onto the IPRL 
apparatus in the presence of perfusate was evaluated as a function of time by comparing 
tobramycin concentration at each sample time point with the spiked tobramycin concentration of 
100 ng/mL, using mixed-effects repeated-measures ANOVA with p value 0.05 by JMP 8.0, to 
assess whether there was statistically significant drug loss during circulation of this tobramycin 
perfusate solution through the IPRL apparatus system for 2 hours.  
 
AI.c  Results and discussion 
 
Chromatograms and mass spectrums  
Volatile ion pairing agent TFA was employed in this study to achieve analyte retention in the 
C18 column. The retention time of tobramycin was increased and peak shape was improved by 
increasing the concentration of TFA in the mobile phase as shown in Figure AI.1. A mobile phase 
consisting ACN-0.1% v/v TFA (30:70) was chosen because of the improved chromatographic 
performance that resulted from this condition in which the analyte showed moderate retention at 
5.4 min and a symmetric peak shape 
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Figure AI.1 Effects of TFA concentration in mobile phase on chromatography. 
Mobile Phase   ACN ‐0.1% v/v TFA  (30:70)
Mobile Phase   ACN‐ 0.05% v/v TFA  (30:70)
Mobile Phase   ACN ‐ 0.025% v/v TFA  (30:70)
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                                                           Figure AI.2 Mass spectrum of tobramycin 
 
The mass spectrum of tobramycin is shown in Figure AI.2 in which peaks corresponding to the 
molecular ions [M+H]+ at m/z 468.65 was observed in addition to the daughter ions at m/z 324.46, 
and 163.11, resulting from cleavage of glycosidic bonds and the subsequent loss of the aminosugar 
rings (Li et al., 2009). The molecular ion [M+H]+ at m/z 468.65 was chosen for single ion 
monitoring in this method for its greatest abundance and specificity. 
Solid phase extraction and sample pretreatment. 
The perfusate matrix is the modified Krebs-Henseleit buffer containing 4% (w/v) bovine serum 
(BSA). The large amount of buffer salts and albumin in the perfusate made direct injections of 
samples onto the LC column followed by mass spectrometric detection impossible. Therefore, 
solid phase extraction was employed for the sample pretreatment after a deproteination procedure 
[M+H]
+ 
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with 5% v/v HFBA, before loading to C18 SPE cartridges. With these sample preparation 
procedures, a complete extraction was achieved with good reproducibility (see Accuracy, precision 
and extraction recovery in Table AI.3). Since the extraction recovery appeared to be complete and 
reproducible, the use of an internal standard seemed not to be necessary. Therefore, the 
quantification was based on the external standard method and validated as suitable for the assay 
of tobramycin in perfusate. 
Although aminoglycosides’ adsorption on container surfaces has been known and reported 
(Josephson et al., 1979), very few published bioanalytical methods addressed the problem. For 
tobramycin solutions in solvents such as water, water/acetonitrile mixture, or with mobile phase 
modifier agents such as TFA, there are no specific studies regarding aminoglycosides adsorption 
from solution on container surfaces. In this study, tobramycin adsorption onto the surfaces of 2 
mL glass HPLC vials versus 250 μL polypropylene (PPE) inserts was evaluated when tobramycin 
standard solutions were prepared in different vehicles such as water, ACN-H20, ACN-H20 
containing TFA. As for the storage in 2mL HPLC glass vials, the detected concentrations of 
tobramycin standard solutions in water or ACN–H2O (80:20) at concentration of 1000 ng/mL were 
observed to decrease 44.3% after 2 hours and the peak of tobramycin was hardly detected after 9 
hours, while 1000 ng/mL tobramycin in ACN –H2O (80:20) containing 0.4% v/v TFA showed no 
change of the detectable concentration (data not shown). While ACN –H2O (80:20) containing 0.4% 
v/v TFA as dilution solvent appeared to prevent tobramycin adsorption,  the tobramycin peak for 
100 ng/mL tobramycin standards prepared with this solvent was split in the tail or showed a 
shoulder when stored in glass vials. Interestingly, tobramycin peak was symmetric and absent of 
tail or peak shoulder for the same solution when a PPE insert was used for HPLC injections. 
Moreover, PPE containers could effectively reduce the drug’s adsorption onto surfaces. However, 
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when tobramycin standards were stored in PPE inserts, the detected concentrations of 100 ng/mL 
decreased by 69.9 and 74.6 ng/mL after 9 hours in water and ACN–H2O (80:20), respectively. 
Using ACN–H2O (80:20) containing 0.4% v/v TFA as the solvent, the detectable concentrations 
of these standards at 100, 500 and 1000 ng/mL showed no decrease after 9 hours (see Table AI.1). 
In conclusion, PPE inserts used with a dilution solvent containing 0.4% TFA removed the 
adsorption problem. Furthermore, assay precision was also improved when this dilution solvent 
was employed (Table AI.2). 
 
Table AI.1 Detectable concentrations of tobramycin standard solutions prepared in ACN–H2O 
(80:20) containing 0.4% v/v TFA at 100, 500 and 1000 ng/mL stored in PPE inserts for 9 h at room 
temperature before injection. 
 
 
 
 
 
 
 
Table AI.2 Precision of repeated injection of 100 ng/mL tobramycin standard prepared in 
different dilution solvents. 
 
 
 
 
  
 
Validation 
 
Calibration Figure AI.3 shows the calibration curve for tobramycin standards in perfusate (7 
concentration levels, 50-5000 ng/mL) using an external standard. The peak area of tobramycin 
Nominal Conc.(ng/ml) 
After 9 h storage in PPE inserts 
(Mean Conc.±SD)  
1000  1003.9±91.5  
500  491.3±22.4  
100  104.9±6.9  
Dilution solvent 
5 runs Precision 
(CV%) 
ACN-H20 (30:70) 0.1% TFA 14.3% 
ACN-H20 (30:70) 0.4% TFA 19.0% 
ACN-H20 (80:20) 0.1% TFA 13.1% 
ACN-H20 (80:20) 0.4% TFA 5.3% 
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versus the nominal concentrations in the standards was best fitted with a quadratic equation 
(software: Masslynx NT 3.5) to provide the solid curve with correlation coefficient equal to 0.995. 
The % deviation of the determined concentrations for each calibrator to the nominal ones were all 
within 11% as shown in Figure AI.3.  
 
 
 
                                   Figure AI.3 Calibration curve of tobramycin standards in perfusate 
 
 
Accuracy, precision and extraction recovery 
Accuracy, precision and extraction recovery of solid phase extraction for quality controls of 
tobramycin in perfusate are presented in Table AI.3. Accuracies ranged from 89.9 to 102.3% 
Nominal Conc 
(ng/mL) %Dev 
5000 -3.2 
2000 10.5 
1000 4.5 
500 -1.5 
200 -14 
100 -2.4 
50 4.4 
Compound name: Tobi
Coefficient of Determination: 0.995202
Calibration curve: 0.000715121 * x^ 2 + 6.96625 * x + -59.9471
Response type: External Std, Area
Curve type: 2nd Order, Origin: Exclude, Weighting: 1/x^ 2, Axis trans: None
0 500 1000 1500 2000 2500 3000 3500 4000 4500
ng/ml-60
52649
Response
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and precision, expressed as CV%, were within 5.5% for tobramycin quality control standards at 
LLOQ, low, medium and high concentration levels. The extraction recovery rates of solid phase 
extraction for quality controls at low, medium and high concentrations were 101.6%, 103.7% and 
97.5%, respectively. LLOQ was set to 50 ng/mL, according to the FDA guidance for Bioanalytical 
Method Validation that required accuracy at this concentration level ranging from 80-120% of 
nominal and precision (CV%) of repeated measurements less than 20% 
(http://www.fda.gov/downloads/Drugs/Guidances/ucm070107.pdf).  
 
Table AI.3 Accuracy, precision and extraction recovery 
Nominal 
Conc. 
(ng/mL) 
Accuracy (%) Precision Recovery (%) 
3 replicates 3 replicates 3 replicates 
Mean SD CV% Mean SD 
5000 93.9 3.0 4.0 101.6 4.3 
1000 102.3 4.1 3.8 103.7 4.6 
100 89.9 3.8 5.5 97.5 4.5 
50 101.8 2.8 2.6   
 
 
Matrix effects 
Reconstituted solutions of “drug-free” perfusate residues were injected to the HPLC column as 
described in the post-column infusion method. The chromatograms are shown in Figure AI.4. Ion 
suppression occurred at a retention time of 4.5 and 5.7 min, while ion enhancement occurred at 
6.4 min for all the injections of these “drug-free” perfusate samples (Figure AI.4). These effects 
did not complicate tobramycin determinations (retention time = 5.4 min, Figure AI.1). The 
chromatogram of blank perfuate showed no obvious difference from those from the 4 batches of 
IPRL control perfusate (See Figure AI.4). Likewise, there was no detectable difference in the 
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chromatograms when the perfusate was recirculated in the pulmonary vasculature of the IPRL for 
either 0.5 or 2 h (Figure AI.4) and also no detectable difference for the IPRL control perfusate 
obtained from different rats (data not shown).  Although the peak of tobramycin (retention time at 
5.4 min) could be resolved even with matrix effects, further confirmation was performed using the 
post-extraction addition method to assess whether the residuals  (after solid phase exaction) of 
perfusate components and endogenous metabolic byproducts from the dying tissue during 
recirculation in the rat lung vasculature affected the assay’s accuracy. Table AI.4 shows % 
deviation (% dev.) of mean peak area obtained from the injections of tobramycin standards 
prepared with perfusate matrix ܣݎ݁ܽ௣௢௦௧ି௘௫௧௥௔௧ప௢௡	തതതതതതതതതതതതതതതതതതതതതതതത from that in the reference solutions (the 
standard solution prepared in the absence of perfusate matrix), ܣݎ݁ܽ௥௘௙௘௥௘௡௖௘തതതതതതതതതതതതതതതതത.  In these results, the 
values of % dev. for low (100 ng/mL), medium (100 ng/mL) and high (5000 ng/mL) concentrations 
were within 15%, indicating that the matrix components in the blank perfusate and IPRL control 
perfusate re-circulating in the isolated rat lung vasculature did not change the assay’s accuracy for 
spiked standards prepared in the presence of extracted perfusate. These results also implied that 
this solid phase extraction technique could effectively remove interfering matrix components other 
than the analyte.   
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Figure AI.4 Chromatograms of perfusate with post-column infusion of 1 µg/mL  
standard solution 
 
 
     Table AI.4  % dev. of mean peak area of tobramycin in perfusate matrices (extracted) from that 
in the reference solutions (standard solutions prepared in the absence of perfusate matrices)  
Nominal 
Conc. 
(ng/mL) 
for “IPRL-free” blank 
perfusate  
 for IPRL control perfusate that 
recirculated in the pulmonary 
vasculature of the rat lung for 2h 
% dev.  % dev. 
5000 2.1 -2.7 
1000 5.7 5.7 
500 7.1 -6.5 
100 13.8   8.3 
 
 
Adsorption tests in the IPRL apparatus 
 
Circulating tobramycin perfusate solution in the IPRL apparatus in the absence of rat lungs at 
37°C for 2 hours failed to show a concentration decrease due to adsorption loss to the apparatus.  
The determined concentrations at each sampling time showed no significant changes from the 
 Blank perfusate
Batch 3: Control perfusate recirculated in IPRL for 0.5 h
Batch 4: Control perfusate recirculated in IPRL for 2 h
97 
 
nominal concentration of 100 ng/mL over 2 hours using mixed-effects repeated-measures ANOVA 
(p value > 0.05; Figure AI.5). It is possible that the high content of BSA in the perfusate effectively 
prevented the drug’s adsorptive losses onto the apparatus in this case. 
 
 
 
Figure AI.5 Adsorption test of tobramycin on the IPRL apparatus 
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Appendix II 
RADIOACTIVE [3H]TOBRAMYCIN SPECIFICATIONS 
 
 
 
This shows a copy of certificate of analysis and product data sheet with analytical 
specifications provided by Moravek Biochemicals, Inc. Brea, CA. The claimed radiochemical 
purity of the tritiated drug was 98.5% on Dec. 14, 2011.  
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Appendix III 
RADIOACTIVE [3H]TOBRAMYCIN ASSAY IN PERFUSATE 
 
 
 
Perfusate samples containing [3H]tobramycin obtained from IPRL experiments were assayed 
in a Liquid Scintillation Analyzer (LSA) (Tri-Carb 2800-TR, PerkinElmer) directly or after 
appropriate dilution in blank perfusate; the counts were corrected by subtracting the background 
due to blank perfusate. Tobramycin concentrations in perfusate samples for each IPRL experiment 
were calculated based on the comparison of radioactive content between perfusate samples and the 
dosing solution used in the same IPRL study. For each IPRL experiment, the dosing solution 
prepared with trace amount of [3H]tobramycin was diluted 2000 fold by blank perfusate to prepare 
the control solution for the assay. The total radioactivity in samples, expressed as DPMs 
(disintegrations per minute), in 1 mL of each solution was determined by LSA, after mixing with 
5 mL of scintillation cocktail (Ecoscint XR, National Diagnostics, Atlanta, GA) followed by 4 
hours of storage in the dark at room temperature prior to analysis. Control solutions were prepared 
in duplicate. Corrected DPMs of perfusate samples were used for calculation of tobramycin 
concentration, Csample, according to the formula:  
Csample = DPMsample / mean DPMcontrol × ܥ௖௢௡௧௥௢௟௡௢௠௜௡௔௟                                            eq. AIII.1 
where DPMsample and mean DPMcontrol are the corrected radioactive counts from samples and 
duplicate controls, respectively, while  ܥ௖௢௡௧௥௢௟௡௢௠௜௡௔௟   refers to the nominal concentration of each 
control solution (0.5‰ of solute concentration in dosing solution).  
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A comparison of the HPLC-MS and radioactive analysis methods is shown for tobramycin 
absorption in Appendix IV. Notably, such a comparison could only be performed at a relatively 
high dose (2mg) that produced perfusate concentrations enabling accurate assay by HPLC-MS. 
Radioactive methods were needed for lower doses. 
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Appendix IV 
COMPARISON OF IPRL ABSORPTION DATA FOR TOBRAMYCIN: 
RADIOACTIVITY ASSAY VERSUS HPLC-MS 
 
 
 
AIV.a Introduction 
The HPLC-MS method described in Appendix I successfully assayed tobramycin perfusate 
samples at concentrations no less than 50 ng/mL. Nevertheless, the detection sensitivity was not 
sufficient for the studies of tobramycin absorption in the IPRL at doses lower than 0.2 mg, in which 
tobramycin concentrations in the re-circulating perfusate in most cases were < 50 ng/mL if sample 
time less than 10 minutes following administration. In order to study tobramycin’s disposition 
kinetics for a wide range of airway doses (from 0.002 to 2 mg) in the IPRL therefore, a radioactivity 
assay using liquid scintillation counting (described in Appendix III) was employed. This appendix 
describes a comparison of the cumulative fraction of administered dose absorbed into the perfusate, 
Fp, as a function of time, from two parallel groups of IPRL absorption experiments in which the 
surgery, establishment and maintenance of the IPRL, and the dosing technique and perfusate 
sampling, were all fixed except perfusate samples were assayed either by HPLC-MS or 
radioactivity. The Appendix also describes the general methods used to calculate Fp from the 
concentration data that was collected in each experiment. 
 
AIV.b Methods 
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IPRL absorption studies using either tritium-labeled tobramycin or unlabeled tobramycin were 
performed according to Chapter IV. For six separate IPRL absorption experiments using 
tobramycin dosing solution at 20 mg/mL containing 18μCi/mL [3H]tobramycin, perfusate samples 
were analyzed by radioactivity assay as described in Appendix III. For 4 separate IPRL absorption 
experiments using unlabeled tobramycin solutions at 20 mg/mL, perfusate samples were analyzed 
using the HPLC-MS method described in Appendix I.  For each IPRL experiment, tobramycin 
concentrations in the re-circulating perfusate at each sampling time, ܥ௧௣௘௥௙௨௦௔௧௘, were determined 
to calculate the cumulative absorbed amount from airway to the perfusate, and the cumulative 
fraction of administered dose absorbed into the perfusate (Fp) by the equation: 
ܨ୔ ൌ ஼೟
೛೐ೝ೑ೠೞೌ೟೐ൈ௏೟ା∑ሺ஼ೞೌ೘೛೗೐ൈ௏ೞೌ೘೛೗೐ሻ
஺ௗ௠௜௡௜௦௧௘௥௘ௗ	ௗ௢௦௘ 	                                  eq. AIV. 1 
where ܥ௧௣௘௥௙௨௦௔௧௘ and  ௧ܸ are the drug concentration in the circulated perfusate and the total 
volume of the re-circulating perfusate in the IPRL system at time t, respectively;   ܥ௦௔௠௣௟௘	is the 
drug concentration in each perfuate sample, and ܸ௦௔௠௣௟௘ is the volume of that perfusate sample 
withdrawn at each sampling time (=1mL);	∑ሺܥ௦௔௠௣௟௘ ൈ ܸ௦௔௠௣௟௘ሻ is the total amount of drug in 
perfuate samples taken before time t.  Notably, no blank perfusate was added to replace perfusate 
after each sample was withdrawn in IPRL absorption experiments. After the last time point, the 
recirculating perfusate was collected and measured, to determine ௟ܸ௔௦௧ and used to calculate ௧ܸ. 
The values of Fp at each sampling time were compared statistically between the two assay methods 
using multiple t tests and a p value 0.05. 
 
AIV.c Results and discussion 
For each IPRL experiment, sampling time,	ܥ௧௣௘௥௙௨௦௔௧௘, ௧ܸ , cumulative amount of dose absorbed 
into perfusate from the airway, and Fp are tabulated in Table AIV.1 (using the radioactivity assay) 
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and Table AIV.2 (using the HPLC-MS method). The mean±SD of Fp values at each sampling time 
determined by the HPLC-MS method and the radioactivity assay are shown in Fig. AIV.1. For the 
IPRL experiments using the HPLC-MS method, there were not sufficient data at 1, 105 and 120 
minutes to perform a statistical comparison. The comparison of Fp therefore, was performed at 3, 
5, 10, 20, 30, 40, 50, 60, 75, 90 minutes for the two parallel groups of IPRL absorption experiments. 
There was no statistical difference of the values Fp between the two parallel groups at any of these 
sampling times (t-test, p value >0.5), indicating that the IPRL absorption results were consistent 
when the two different assay techniques were employed. The results implied that assaying 
perfusate samples based on radioactivity content by LSA were accurate and specific for 
tobramycin since the IPRL absorption data determined by this technique were comparable with 
those determined by the HPLC-MS method in which tobramycin was quantitated using single ion 
monitoring of tobramycin’s molecular ion [M+1]+.  
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Figure AIV.1 Mean cumulative fraction of administered tobramycin dose absorbed into perfusate 
versus time determined by HPLC-MS or the radioactivity assay (nominal doses are 2 mg) 
 
 
Table AIV.1 IPRL absorption data of tobramycin determined by radioactivity assay (6 IPRL 
preparations) 
 
Rat Lung #1 [3H]tobramycin   
Administered dose 2027.5 μg  
Sampling time 
(min) 
ܥ௧௣௘௥௙௨௦௔௧௘  
(µg/mL) 
௧ܸ  
(mL) 
Cumulative 
absorbed amount 
(μg) Fp 
1 0.632 200 126.44 0.062 
3 1.559 199 310.93 0.153 
5 2.316 198 460.82 0.227 
10 2.980 197 591.54 0.292 
15 3.490 196 691.52 0.341 
20 3.608 195 714.58 0.352 
30 4.443 194 876.62 0.432 
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40 4.609 193 908.66 0.448 
50 4.640 192 914.60 0.451 
60 5.204 191 1022.20 0.504 
75 5.705 190 1117.42 0.551 
90 5.895 189 1153.33 0.569 
105 6.338 188 1236.66 0.610 
120 6.632 187 1291.67 0.637 
 
Rat Lung # 2 [3H]tobramycin   
Administered dose 2289.4 μg  
Sampling time 
(min) 
ܥ௧௣௘௥௙௨௦௔௧௘  
(µg/mL) 
௧ܸ  
(mL) 
Cumulative 
absorbed amount 
(μg) Fp 
1 0.765 213 162.95 0.071 
3 1.108 212 235.61 0.103 
5 1.409 211 299.24 0.131 
10 2.029 210 429.43 0.188 
15 2.420 209 511.02 0.223 
20 2.953 208 621.86 0.272 
30 3.351 207 704.30 0.308 
40 3.865 206 810.32 0.354 
50 4.069 205 852.03 0.372 
60 4.647 204 970.02 0.424 
80 4.998 203 1041.27 0.455 
90 5.384 202 1119.19 0.489 
105 5.881 201 1219.18 0.533 
120 6.153 200 1273.47 0.556 
 
 
Rat Lung # 3 [3H]tobramycin   
Administered dose 2255.2 μg  
Sampling time 
(min) 
ܥ௧௣௘௥௙௨௦௔௧௘  
(µg/mL) 
௧ܸ  
(mL) 
Cumulative 
absorbed amount 
(μg) Fp 
1 1.033 213 219.93 0.098 
3 1.598 212 339.88 0.151 
5 2.106 211 446.95 0.198 
10 3.326 210 703.21 0.312 
15 4.026 209 849.58 0.377 
20 4.549 208 958.19 0.425 
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30 5.152 207 1083.12 0.480 
40 5.036 206 1174.48 0.521 
50 5.359 205 1247.49 0.553 
60 5.972 204 1385.87 0.615 
75 6.682 203 1394.54 0.618 
90 6.926 202 1443.89 0.640 
105 7.236 201 1506.28 0.668 
120 6.325 200 1640.36 0.727 
 
Rat Lung # 4 [3H]tobramycin   
Administered dose 1800.7 μg  
Sampling time 
(min) 
ܥ௧௣௘௥௙௨௦௔௧௘  
(µg/mL) 
௧ܸ  
(mL) 
Cumulative 
absorbed amount 
(μg) Fp 
1 0.708 204 144.35 0.080 
3 1.441 203 293.20 0.163 
5 1.920 202 389.95 0.217 
10 2.733 201 553.31 0.307 
15 3.236 200 653.94 0.363 
20 3.460 199 698.65 0.388 
30 3.931 198 791.84 0.440 
40 4.205 197 845.77 0.470 
50 4.456 196 895.05 0.497 
60 4.682 195 939.00 0.521 
75 4.428 194 889.74 0.494 
90 5.150 193 1029.23 0.572 
120 5.243 192 1046.92 0.581 
          
 
Rat Lung # 5 [3H]tobramycin   
Administered dose 1953.22 μg  
Sampling time 
(min) 
ܥ௧௣௘௥௙௨௦௔௧௘  
(µg/mL) 
௧ܸ  
(mL) 
Cumulative 
absorbed amount 
(μg) Fp 
1 0.885 203 179.69 0.092 
3 1.343 202 272.14 0.139 
5 1.665 201 336.84 0.172 
10 2.276 200 459.12 0.235 
15 2.844 199 572.26 0.293 
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20 3.008 198 604.74 0.310 
30 3.524 197 706.46 0.362 
40 3.964 196 792.58 0.406 
50 4.168 195 832.60 0.426 
60 4.549 194 906.52 0.464 
75 4.831 193 961.14 0.492 
90 5.076 192 1008.27 0.516 
105 5.329 191 1056.71 0.541 
120 5.648 190 1117.61 0.572 
 
Rat Lung # 6 [3H]tobramycin   
Administered dose 1926.2 μg  
Sampling time 
(min) 
ܥ௧௣௘௥௙௨௦௔௧௘  
(µg/mL) 
௧ܸ  
(mL) 
Cumulative 
absorbed amount 
(μg) Fp 
1 0.977 202 197.36 0.102 
3 2.197 201 442.56 0.230 
5 2.918 200 586.72 0.305 
10 3.906 199 783.47 0.407 
15 4.267 198 854.93 0.444 
20 4.531 197 906.82 0.471 
30 5.152 196 1028.52 0.534 
40 5.319 195 1061.15 0.551 
50 5.328 194 1062.85 0.552 
60 5.310 193 1059.40 0.550 
75 5.438 192 1084.06 0.563 
90 5.914 191 1174.89 0.610 
105 6.139 190 1217.67 0.632 
120 6.218 189 1232.62 0.640 
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Table AIV.2 IPRL absorption data of tobramycin determined by HPLC-MS assay (4 IPRL 
preparations) 
 
Rat Lung #7 unlabeled tobramycin   
Administered dose 1791.5 μg  
Sampling time 
(min) 
ܥ௧௣௘௥௙௨௦௔௧௘  
(µg/mL) 
௧ܸ  
(mL) 
Cumulative 
absorbed amount 
(μg) Fp 
          
3 1.908 204 389.25 0.217 
5 2.456 203 500.52 0.279 
10 3.032 202 616.87 0.344 
15 3.271 201 664.84 0.371 
20 3.525 200 715.62 0.399 
30 3.828 199 775.94 0.433 
40 4.023 198 814.59 0.455 
50 4.448 197 898.26 0.501 
60 4.489 196 906.24 0.506 
75 4.721 195 951.52 0.531 
90 4.702 194 947.98 0.529 
     
     
Rat Lung #8 unlabeled tobramycin   
Administered dose 1814.1 μg  
Sampling time 
(min) 
ܥ௧௣௘௥௙௨௦௔௧௘  
(µg/mL) 
௧ܸ  
(mL) 
Cumulative 
absorbed amount 
(μg) Fp 
1 1.118 200 223.66 0.123 
3 1.854 199 370.04 0.204 
5 2.271 198 452.60 0.249 
10 2.696 197 536.37 0.296 
15 3.057 196 607.06 0.335 
20 3.195 195 633.96 0.349 
30 3.524 194 697.79 0.385 
40 3.477 193 688.77 0.380 
50 3.750 192 741.22 0.409 
60 3.850 191 760.31 0.419 
75 4.340 190 853.43 0.470 
90 4.342 189 853.78 0.471 
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Rat Lung # 9 unlabeled tobramycin   
Administered dose 1799.2 μg  
Sampling time 
(min) 
ܥ௧௣௘௥௙௨௦௔௧௘  
(µg/mL) 
௧ܸ  
(mL) 
Cumulative 
absorbed amount 
(μg) Fp 
1 0.452 200 90.49 0.050 
3 1.066 199 213.23 0.119 
5 1.534 198 306.28 0.170 
10 2.167 197 431.76 0.240 
15 2.710 196 537.47 0.299 
20 3.057 195 604.14 0.336 
30 3.726 194 732.36 0.407 
40 4.211 193 823.71 0.458 
54 4.392 192 855.60 0.476 
60 4.646 191 900.54 0.501 
75 5.033 190 970.36 0.539 
90 5.299 189 1016.43 0.565 
     
     
     
Rat Lung # 10 unlabeled tobramycin   
    
Administered dose 1834.7 μg  
Sampling time 
(min) 
ܥ௧௣௘௥௙௨௦௔௧௘  
(µg/mL) 
௧ܸ  
(mL) 
Cumulative 
absorbed amount 
(μg) Fp 
3 0.209 203 42.44 0.023 
5 0.365 202 73.84 0.040 
10 0.852 201 171.79 0.094 
15 1.492 200 299.83 0.163 
20 1.699 199 341.00 0.186 
30 2.385 198 476.87 0.260 
40 2.888 197 575.97 0.314 
50 3.396 196 675.51 0.368 
60 3.939 195 781.42 0.426 
75 4.502 194 890.52 0.485 
90 5.047 193 995.86 0.543 
105 5.238 192 1032.54 0.563 
120 5.491 191 1080.73 0.589 
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